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Abstract

Poly(ester amide)s (PEA)s offer several properties superior to currently used
systems such as fewer acidic degradation products and functional handles for the
conjugation of bioactive molecules. Herein, two novel PEA based drug delivery systems
were developed and evaluated. The first utilizes PE As containing pendant carboxylic acid
functional groups and was evaluated with respect to its ability to control the release of a
model drug, a Rhodamine B derivative. The drug exhibited sustained release without a
burst phase, demonstrating the utility of the carboxylic functional handles. A second drug
delivery system was prepared utilizing novel polyethylene oxide)-PEA copolymers
which formed into micelles. The resulting system was capable o f encapsulating and
releasing Nile Red, a model hydrophobic drug, on a pharmacologically relevant time
scale. Overall, these results suggest that PEAs are excellent biomaterials, capable of
delivering therapeutics and have the potential to overcome many o f the deficiencies
found in current delivery systems.
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Chapter One:
Introduction
1.1

Drug Delivery

Recently the pharmaceutical and biotechnology industries have developed a wide
array of drug candidates. While many of these therapeutics have remarkable potential,
they remain ineffective unless they can be successfully delivered. The successful clinical
application of these formulations requires an engineering approach, which addresses drug
stability, administration, absorption, metabolism and bioavailability at the target site,
however, many currently used systems are inadequate in one or more of these factors.1
Problems such as low drug solubility2 and rapid renal clearance3 affect bioavailability,
while the harsh in vivo conditions may cause loss of bioactivity.4 Some therapeutics, such
as protein drugs, are particularly susceptible to many of these factors, making them
difficult to deliver via oral administration, ’ the most convenient mode of drug delivery,
due to its ease of use and high patient compliance. In order to maintain bioactivity of
these susceptible drugs, administration via the parenteral route may be necessary.7 An
attractive method to minimizing discomfort and improving patient compliance is to
develop sustained-release formulations with well defined release kinetics. A slower
release rate will reduce the number of injections a patient will require, as long as stability
is unaffected, and delivery of drugs with narrow therapeutic windows is safer and more
convenient when delivered through a system with well defined kinetics. As seen in Figure
1.1, when delivering via a traditional free drug approach, the concentration of drug within
the blood may vary significantly over time. The concentration can fall above or below the

2
therapeutic range due to issues such as poor patient compliance. In contrast, by
employing a sustained release vehicle, the rate of drug release can be optimized to stay
within the therapeutic range and less frequent dosing is required. Another benefit of using
a delivery system is the potential to target certain tissues. Particles circulating for
extended periods can accumulate in cancerous tissues while particles decorated with
targeting moieties may greatly increase local concentrations of drugs while having
minimal effect on other tissues.6 Nanoscale systems offer a promising means of
overcoming many issues arising in drug delivery which are discussed in detail below.

As blood circulates, it passes through the kidneys where the glomerulus filters out
solutes, waste products, and excess water.8 The epithelial cell coating of the glomerulus

3
contains pores ranging in size from 4 nm to 14 nm; thus, circulating macromolecules
with hydrodynamic radii smaller than the glomerular pores will permeate the membrane
and be excreted. Polymers with hydrodynamic radii small enough to permeate, tend to
have molecular weights (MW)s between 30000 and 50000 g/mol9 though this range is an
estimate as shape, flexibility and polymer chemistry can have a large effect on
hydrodynamic radius. Many current pharmaceuticals are well below this MW range and
are readily excreted, reducing their circulation time and biological activity. By
encapsulating a drug within a nanoparticle (NP), renal clearance can be avoided, greatly
enhancing the drug’s circulation time and thus potentially the therapeutic efficacy.8

1.3

Reticuloendothelial System

In addition to clearance by the kidneys, free drugs may be removed via the
reticuloendothelial system (RES). In a process called opsonization, a circulating protein,
opsonin, binds to foreign particles, increasing the ability of phagocytic cells to recognize
the foreign substance.10 Particles which are over 200 nm in diameter, highly charged or
hydrophobic particles are highly susceptible to opsonin binding and removal via the RES.
Once bound by opsonin, the liver and spleen can more effectively remove these
circulating particles or phagocytic cells can break them down to be removed by the
lymphatic system.9

4

1.4

Targeting

Nanoscale drug delivery systems can achieve tumour targeting through two
mechanisms: passive and active targeting. Passive targeting involves the prolonged
circulation of the carrier and its preferential accumulation in cancerous tissue. In contrast,
active targeting requires incorporated ligands on the nanocarrier surface which bind
specifically to receptors on a certain cell type’s surface, thereby promoting nanocarrier
cell interaction and cellular internalization. The two methods of targeting are described in
detail below.

1.4.1

Passive Targeting

Cancerous tissue requires an ever-increasing supply of nutrition and oxygen to
meet the requirements of its rapid growth. As a result, the neovasculature of cancerous
\

tissue greatly differs from that found in healthy tissue- a dichotomy which is visible
through variation in shape, excessive dilation, poor alignment, disorganization and the
presence of large fenestrations.9 In addition, perivascular cells and the basement
membrane in the vascular wall tend to be either absent or abnormal in cancerous tissue.
These anatomical defects present in the tumor vasculature promote extensive leakage of
circulating blood components into the tumor.

Along with this blood, circulating

macromolecules in the size range of 20 nm to 200 nm have been shown to preferentially
extravasate into the cancerous tissue.1,9,11,12 Once macromolecules have permeated into
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•the interstitium, the ill-defined lymphatic network in the tumor is unable to effectively
remove them, causing the local concentration to rise by as much as 50 times.9 The
abnormally high levels of extravasation, coupled with the below average venous return
and poor lymphatic clearance, result in the accumulation of macromolecules within the
tumor interstitium. This phenomenon has been termed the enhanced permeability and
retention (EPR) effect. It is important to note that the EPR effect does not apply to free
drugs with low molecular weights because they diffuse rapidly back into the circulating
blood and are highly affected by renal filtration, which removes them from the blood
before they have time to accumulate.

1.4.2

Active Targeting

As there is no direct interaction between a nanoscale delivery system and
cancerous tissue during the passive targeting of the EPR effect, the penetration of the
carrier is limited.13 In order to increase cell penetration, attaching targeting ligands to the
carrier surface is an attractive option. The practice of active targeting is based primarily
on:13
i)

the overexpression of specific antigenic receptors on the surface of cancer cells
relative to cells in normal tissues,

ii)

the specificity and high binding affinity of targeting ligands to receptors,

iii)

the intracellular delivery possible by cell mediated endocytosis via the ligandreceptor interaction.

'
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Although targeting of cancer cells is a wide field, with a variety of different
approaches, two of the most important targeting modalities are angiogenesis and
uncontrolled cell proliferation.
Angiogenesis is characterized by the invasion, migration and proliferation of
smooth muscle and endothelial cells.14 These cells then degrade the basement membrane
and form a new lumen structure. Tumour cells infiltrate the newly developed lumen
structure and secrete a variety of proangiogenic factors15 and once adequately
vascularized, the cancer may translate into a metastatic form and spread to other parts of
the body.16 By attacking the growth of the blood supply, the abnormally high blood
requirement can be exploited to limit the metastatic capabilities and size of tumours.
This angiogenic approach offers many advantages over traditional therapies:13'18

i)

destroying the vasculature decreases the growth and metastatic capabilities
of the tumour,

ii)

neovascular endothelial cells are less able to undergo phenotypic
variations, diminishing secondarily acquired drug resistance found in
, conventional cancer therapies,

iii)

■

the tumour vasculature is not specific for the type of cancer.

The main angiogenic targets explored by NP systems for therapeutic benefit
include: the vascular endothelial growth factor receptors (VEGFR)s,19 avp3 integrins,13
matrix metalloproteinase receptors (MMP)s,
(VCAM-1).21

on

and vascular cell adhesion molecule-1
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Alternately, cell proliferation markers are excellent targets for cancer
therapeutics as many are over-expressed on tumour cells. NPs can be actively targeted by
the incorporation of monoclonal antibodies to target cell proliferation receptors.22 The
four basic targeting criteria of monoclonal antibodies for cancer therapeutic application

i)

the antigen of interest is over-expressed by tumour cells,

ii)

the antigen participates as a principle component in the progression of the
■.disease,:

-

•-

iii)

the antigen is stable in its present form upon the tumour cell surface,

iv)

the antigen is expressed by a large percentage of tumour cells and a large
variety of tumours.

Uncontrolled cell proliferation targets tend to be used more regularly by actively
targeting NPs. The most established targets include: human epidermal receptors (HER),
transferrin receptors, and folate receptors.
,

:

The HER family of receptor tyrosine kinases contains two highly upregulated

targets on tumour cell surfaces, epidermal growth factor, receptor (EGFR) and human
epidermal receptor-2 (HER-2). Both are known to mediate a cell signaling pathway for
growth and proliferation in response to the binding of the growth factor ligand and are
among the most heavily researched proliferation targets.

'yx

Clinical studies using

monoclonal antibody blockade and EGFR tyrosine kinase inhibitors have suggested that
EGFR blockade is a well-tolerated and effective treatment strategy.

24. 21

“
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Both metastatic and drag resistant cells have an elevated number of transferrin
receptors relative to healthy cells, making it a pertinent target for cancer therapeutics.28
Transferrin is a serum, non-heme, iron-binding glycoprotein that helps transport iron to
proliferating cells.

In order to dissociate the iron, transferrin binds to the transferrin

receptors on the cell surface, becomes endocytosed and iron is released due to the lower
\

pH inside the cell. The transferrin receptor is overexpressed in malignant cells due to the
increased iron requirement to fuel the uncontrolled growth of cancerous tissue.
Transferrin receptor targeting for cancer therapeutics has been successfully used in
human clinical trials with adriamycin,

cisplatin,

and diphtheria toxin.

The folate receptor (FR) is a 38 kDa glycoprotein and is one of the most highly
researched targets for cancer treatment. “ Folic acid, also known as vitamin B9, is
necessary for the synthesis, of biologically important molecules such as purines and
pyrimidines

and since mammalian cells are unable to synthesize this vitamin, it must be
)
internalized.38 For non-malignant cells, the reduced-folate carrier is highly specific for
reduced forms of this vitamin, such as 5-methyl-tetrahydrofolate39 but there remains
debate regarding the specificity of the transport of other folate conjugates.13’40“42 It is
possible to design folate-linked pharmaceuticals that only enter cells via an alternative
route, the FR, which is highly expressed in cancer cells, activated macrophages, the
placenta, and the apical surfaces of some polarized epithelia.40,43,44 Fortunately, the FR is
significantly upregulated on many cancer cells, in some cases by two orders of magnitude
relative to healthy tissue.

In addition, folate ligands are attractive because they are

inexpensive, non-toxic, non-immunogenic, relatively easy to conjugate to carriers, retain
high binding affinity, and are relatively stable in both storage and circulation.

ao
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Another advantage of active targeting is the potential to suppress the multidrug
resistance (MDR) condition in which tumours develop resistance to a range of anticancer
chemotherapeutics.45 It has been shown that one method through which breast and
ovarian tumours develop resistance is the overexpression of the p-glycoprotein (P-gp)
transporter efflux pumps.45 This adenosine triphosphate-dependant efflux pump removes
chemotherapeutic agents from the cell, greatly decreasing the therapeutic efficacy of the
treatment.46 A wide selection of commonly used drugs such as: paclitaxel, doxorubicin
(DOX), and vinblastine are removed from cells by these pumps.

However, the route of

entry into a cell by an actively targeted nanocarrier is receptor-mediated endocytosis
which will circumvent the P-gp efflux, thereby increasing overall therapeutic
efficacy.47’48

1.5

Review of Current Drug Delivery Systems

The utility of nanocarriers may be seen by their potential to improve the
c
K

/ therapeutic index of their payloads by increasing drug efficacy, lowering drug toxicity,
and achieving steady state therapeutic levels of drugs over an extended period of time.49
They can also improve drug solubility and drug stability, which allows for the
development of new drugs that could not have been used previously due to
pharmacokinetic or biochemical constraints. To date, the most commonly researched
nanoscale delivery devices include: polymeric NPs,50'55 dendrimers,56'67 nanoshells,68'72
liposomes,28,33’34’47’48’73'75 micelles,76'79 nucleic acid-based NPs,80’83 magnetic NPs,66’84'88
\

and viral NPs.89'91 The utility of these nanotechnologies is becoming increasingly

10
-recognized and several examples of first generation nanocarriers have been approved by
the Food and Drug Administration for therapeutic and diagnostic applications. Of
particular note are: Abraxane, an albumin-bound particle form of paclitaxel,
PEGylated liposome carrier for DOX,

Doxil, a

DaunoXome, a liposomal formulation of

daunorubicin94 and Feridex, a superparamagnetic iron oxide magnetic resonance imaging
contrast agent.95 As the utility of these approved therapeutic and diagnostic tools
becomes more evident, and more research is done in optimizing their properties, new
tools will emerge and become approved for use in vivo.

1.5.1

Polymeric nanoparticles

':

One of the most influential works on polymer NPs written by Langer et al., was
published in Science in 1994 and has been cited almost 1,200 times.96 This article
outlines the desired features of nanoscale carrier including: (i) that the agent to be
encapsulated comprises a reasonably high weight fraction (loading) of the total carrier
system (for example, more than 30%), (ii) that the amount of agent used in the first step
of the encapsulation process is incorporated into the final carrier (entrapment efficiency)
at a reasonably high level (for example, more than 80%), (iii) the ability to be freezedried and reconstituted in solution without aggregation, (iv) biodegradability, (v) small
size (less than 5 pm), and (vi) characteristics to prevent rapid clearance of the particles
from the bloodstream. The particles they created to meet all these criteria were core-shell
NPs made from either poly(lactic-co-glycolic acid) (PLGA), poly(caprolactone) (PCL),
and copolymers of these two. The chemical composition and polymer molecular weight
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-were varied and degradation time and release kinetics were varied accordingly. The
shell material for all particles studied was poly(ethylene glycol) (PEG). Particles were
made by forming an oil in water emulsion with subsequent solvent evaporation. The
resulting particles could be stored, without preservatives, by lyophilization and later
redispersed. Characterization by atomic force microscopy and quasi-elastic light
scattering revealed monodisperse, spherical particles of mean diameter 140 nm. In vivo
studies showed that decreasing PEG loading significantly reduced the circulation time. A
model drug lidocaine, a local anesthetic known to block sodium channels in axons,

was

shown to have a loading of 45% and an entrapment efficiency of over 95%. An important
discovery came from the realization that high drug loadings actually produced slower
release rates. This is counter-intuitive as a higher concentration gradient should cause a
more rapid release. The group hypothesized that higher loadings induced drug
crystallization within the NP. The phase separation requires drug dissolution and then
subsequent diffusion from the particle. The hypothesis was supported by calorimetric and
x-ray diffraction studies. It was proposed that possible uses for the NPs include:
transferrin coupling to allow for endocytosis of a particle containing DNA, antibody
coupling to the PEG end group forming highly specific, targetable entities to desired
tissues, as well as the ubiquitous drug delivery and medical imaging applications.
Since Langer et ah’s article, much interest has been generated for PLGA due to its
biocompatibility and commercial availability in different molecular weights and
copolymer compositions that allow for precise tailoring of release properties and
degradation.98'101 The degradation products of PLGA are non-toxic as the polymer
degrades first into its monomers, lactic and glycolic acid, which enter the Krebs' cycle,
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-are metabolized, and are subsequently eliminated from the body as carbon dioxide and
water;99 however, large accumulations of acidic species have been shown to cause tissue
inflammation and the acidic degradation of the particles may damage the therapeutic
payload.102 Despite this drawback PLGA has been successfully implemented as a
nanocarrier

for

anti-cancer

agents

(paclitaxel and

DOX),103,104 sex

hormones

(estradiol),105’106 anti-leishmanial agents (amphotericin B),107 immunosuppressants
(cyclosporine),108 and hyperlipidemia treatments (atorvastatin, sold under the name
Lipitor).109 In addition, PLGA has been shown to effectively encapsulate antioxidants
such as coenzyme QIO,110 curcumin,111 epigallocatechin gallate (EGCG).112 Combining
drug and antioxidant payloads may help treat co-existing disease states and reduce drug
induced toxicity.113,114 Grama et al. created a library of PLGA NPs by encapsulating a
wide variety of drugs, hormones and antioxidants. It was shown that the emulsiondiffusion-evaporation NP formation procedure was highly versatile and able to
encapsulate all payloads under study with the exception of amphotericin B which was
!

achieved by nanoprecipitation and DOX and EGCG where the double emulsion method
was adopted.115 It was also found that the entrapment of bioactives in NPs resulted in
significantly higher bioavailability in all compounds compared to their respective
conventional forms. One particular example was estradiol which demonstrated 1014%
relative oral bioavailability compared to its simple suspension.115 Additionally, the
nanoparticulate formulation was able to sustain release over 192 h, in spite of the short
half-life of parent molecule.106
Another traditionally used drug delivery platform is chitosan, a natural
polysaccharide composed of P(1 —» 4)-linked glucosamine units together with some
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- proportion of N-acetylglucosamine units. Chitosan occurs rarely in nature, but it is
generally obtained by extensive deacetylation of chitin.116 It exhibits excellent qualities
for drug delivery applications such as biocompatibility, biodegradability, non-toxicity,
mucoadhesivity and the important capacity to increase the penetration of drugs across
mucosal barriers.116 This penetration is beneficial for designing non-invasive routes of
drug administration, such as oral, mucosal (nasal, pulmonary) and ocular routes. Several
methods for obtaining chitosan NPs have been developed, and some of them, such as
ionotropic gelation and complex coacervation, involve very mild preparation conditions.
Ionotropic gelation consists of the ionic crosslinking of chitosan with multivalent
counter-ions such as Fe(CNV4, Fe(CN)g’3, citrate and sodium tripolyphosphate (TPP).
The NPs are obtained by the addition of a dilute chitosan acid solution to a solution of
TPP with stirring. The size of the particles can be controlled by both chitosan and TPP
concentrations and no organic solvents are needed.

This procedure has been frequently

reported in the literature for the preparation of drug-loaded chitosan NPs. Chitosan
particles prepared via ionotropic gelation have been shown to effectively deliver
ammonium glycyrrhizinate,118 proteins,119 insulin,120 and DOX.121 The gelation process
does have drawbacks as the dilute solutions required are inconvenient for scale up and
poor time-stability of the resulting colloidal dispersion may require the addition of
stabilizers. An alternate method, complex coacervation is achieved by mixing two
oppositely charged polyelectrolytes. The poly electrolyte complex separates into a
polymer-rich phase that coexists with a very dilute phase. The polyelectrolyte complex
produced forms an insoluble film or barrier that covers the particles. Hu et al. prepared
chitosan-poly(acrylic acid) (PAA) NPs by the dropwise addition of dilute chitosan
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- solutions (0.02 wt%) into 0.002 wt% PAA aqueous solutions under magnetic stirring.

122

Hu et al. also prepared chitosan-PAA NPs by template polymerization of PAA in a
chitosan solution at 70 °C using K 2S208 as an initiator. After polymerization, aggregates
were separated by filtration and the NPs in the supernatant solution were characterized.
The hollow nanospheres obtained by this procedure were crosslinked with glutaraldehyde
and loaded with DOX.123 It was found that the drug-loading content was up to 4.3% and
the particles were 118 nm in diameter. The NPs were also able to maintain DOX
concentration in the blood for a longer time period relative to free drug. It has also been
shown that chitosan NPs can encapsulate small interfering ribonucleic acid (siRNA)
through complex coacervation of chitosan and polyguluronate. Encapsulation of siRNA
is essential due to its rapid degradation and low intracellular association in vitro and in
vivo. The siRNA-loaded chitosan-based NPs had mean diameters between 110: and 430
nm, and the diameter could be controlled depending on the weight ratio of chitosan and
polyguluronate. The NPs showed low cytotoxicity and were useful in delivering siRNA
to HEK 293FT and HeLa cells, effectively inhibiting the induction of targeting mRNA.124
It can be concluded that, both ionotropic gelation and complex coacervation are
mild and useful procedures for obtaining NPs. It is necessary to start with very dilute
solutions and to control the pH carefully during preparation, purification and storage to
'I

avoid aggregation.116 The particles are versatile and biocompatible making them effective
delivery vehicles although they are still hampered by acidic degradation products and a
lack o f functional handles.
Although targeted polymeric NPs remain a challenge, it is possible achieve
selective delivery.' Allemann et al. have investigated tumour delivery using Trastuzumab
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- targeted polyQactic acid) NP and have found that they specifically and efficiently bind
to cancer cells.125 Similarly, Pan and Feng showed increased cell internalization with
folate receptor-targeted paclitaxel-loaded NPs made with blends of poly(lactic acid)-cotocopheryll poly (ethylene glycol) succinate (TPGS) and carboxylic acid-terminated
TPGS on MCF-7 and C6 glioma cells.126
Although their size precludes them from the class of NPs, Guo et al. have
developed microspheres of amino acid based poly(ester amide)s (PEAs) via an oil in
water emulsion/solvent evaporation

technique.55 The

effects

of PEA polymer

concentration, poly(vinyl alcohol) (PVA) emulsifier concentration, and the homogenizer
speed on the size and morphology of final PEA microspheres were examined by
analyzing their SEM images. It is found that a low PEA concentration, a high PVA
concentration, and a high homogenizer speed are the optimal conditions for minimizing
particle diameter. This method produced microspheres of approximately one micrometer
diameter. The biodegradation behaviours of these microspheres were investigated and it
was found that the degradation was largely based on surface erosion. The particles were
also capable of encapsulating paclitaxel with high efficiency; however, the large particle
size means they will be readily cleared by the RES and the lack of functional handles
limits the possible uses of this system.
Unfortunately, one of the common limitations of many polymeric drug delivery
systems is that they have burst release kinetics.127'129 This burst effect is in most cases an
undesirable effect where a large percentage x>f the drug is released in a short time period.
The burst release tends to be unpredictable and may induce local toxicity. The short halflife of resulting drugs in vivo results in a loss of activity. Releasing too much drug at once
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- is economically and therapeutically wasteful, and the shortened release profile requires
more frequent dosing. In some cases, such as flavours in the food industry and pulsatile
delivery devices, burst may be desirable, but even in these cases the amount of drug
released in the burst is hard to model and control.130,131
In order to address the burst release effect, several approaches have been taken.
The most common approach has been to covalently immobilize the drug molecule within
the particle via a biodegradable linkage to the polymer. One example of such a linkage is
the covalent immobilization of DOX onto the terminal group of PLGA performed by Yoo
et a l} 29 The resulting conjugate could be formed into 350 nm nanospheres in a single oil
in water emulsion and it was shown the particles released the DOX payload over the
course of one month.129 A novel method of removing the burst effect was undertaken by
)
Tong and Cheng by using the drug-initiated, controlled, living polymerization of cyclic
esters.

The hydroxyl groups on paclitaxel were incorporated into poly(lactide) via the

site-specific polymerization of lactide mediated by either a zinc or magnesium complex.
NP with diameters of less than 100 nm and low PDIs were formed through
nanoprecipitation. The burst release was removed and the release of paclitaxel was
significantly slowed. Unconjugated drug exhibited 75% release in one day and the
conjugated system required six days to achieve the same release.

1.5.2

Micellar drug delivery systems

The use of block copolymers in drug delivery was first proposed by Ringsdorf et
al. in the early 1980s.132 The basis of these systems is that block copolymers with large
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- solubility differences between hydrophilic and hydrophobic segments will assemble in
aqueous media into polymeric micelles with a nanoscopic size range with fairly narrow
size distributions.76,133'135 These micelles are characterized by their unique core-shell
architecture where hydrophobic segments are segregated from the aqueous exterior to
form an inner core surrounded by hydrophilic segments. Hydrophobic payloads can be
encapsulated within this core and will be slowly released by diffusion. The encapsulation
and slow diffusion out of micelles can be utilized for drug delivery applications;
however, it is imperative that the drug delivery carrier be formed from a biocompatible
polymer.

The selection of core-forming blocks tends to be limited to a few polymers

such as polypropylene oxide) (PPO),137 poly (y-benzyl-L-glutamate) (PBLG),138
poly(caprolactone) (PCL),138,139 poly(lactic acid) (PLA),140,141 and poly (D,L-lactide)
(PDLLA).142 The encapsulation efficiency of the micelle system is strongly dependent on
the payload/core interaction and increasing the number of available polymers will
increase the variety and effectiveness of nanocarrier delivery systems; Although
therapeutically useful as discussed below, these commonly used core-forming polymers
lack functional handles, which limits their utility.

.

One core-forming polymer that has shown particular utility is PCL, in part due to
possessing relatively more hydrophobic character than other core forming polymers.143
This utility w as exemplified by Allen et al. by encapsulating FK506, otherwise known as
tacrolimus, and L-685,818 which had been previously difficult to deliver. These
neurotrophic agents are used in the treatment of neurodegenerative diseases. The degree
of neurite-like outgrowth achieved in cell cultures investigated was less than that
obtained when the cells were treated with free FK506 or L-685,81, meaning that work

i
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- still must be undertaken in order to optimize this delivery system, In addition, large
aggregates formed during micellation, necessitating filtering prior to use. In a separate
publication, Allen et al. made use of a stronger payload/core interaction and formed a
very effective delivery system for dihydrotestosterone (DHT) using poly(caprolactone)-bpoly(ethylene oxide) micelles.144 The release profile of the drug from the micelle solution
was found to be a slow steady release, which continued over a one-month period. The
biological activity of the micelle-incorporated DHT was found to be fully retained and
the drug loading was an impressive 240%.
Another commonly used class of polymers for micelle formation are poloxamers
(trade name Pluronics). Poloxamers are non-ionic, triblock copolymers formed from a
hydrophobic PPO block flanked by two poly(ethylene oxide) (PEO) blocks. This class of
polymers self-assemble without additional surfactants since the PEO blocks are already
incorporated. Variation of the molecular characteristics such as PPO/PEO ratio and
molecular weight of the copolymers allows for fine control over the physical properties
of the system. As a result, poloxamers are an important class of surfactants which have
found widespread industrial applications in detergency, dispersion stabilization, foaming,
emulsification,

and

lubrication145 along

with more

specialized applications in

pharmaceutics, bioprocessing, and separations.146'149 Poloxamers have shown promise in
avoiding multidrug resistance as well as the potential to cross the blood brain barrier.150
The versatility of this system has been well established by encapsulating a range of
therapeutics into poloxamers of varying MW. For example P I05 has been shown to
effectively encapsulate ruboxyl,151 and DOX151,152 while P85 displayed similar
results153,154 with daunorubicin, DOX, vinblastine, mitomycin C, cisplatin, and taxol.
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Another class of versatile polymers used in micelle preparations are the
poly(ethylene oxide)-b-poly(L-amino acid)s. Physical encapsulation is one means of
loading this class of polymer as seen in Lavasanifar et al.’s work were poly(ethylene
oxide)-b-poly(N-hexylstearate-L-aspartamide)

micelles

amphotericin B (AmB), a potent antifungal agent.

physically

entrapped

The 20 nm micelles resulted in

reduced hemolytic activity compared with free AmB. The drug loading was only 1%;
however, the authors claim that this loading is clinically relevant for use in humans for
systemic fungal diseases. In addition to physical encapsulation, poly(ethylene oxide)-bpoly(L-amino acid)s are appealing as they may facilitate chemical modification post
polymerization through the repeating amino acid, as exemplified by Yokoyama et al.
conjugating DOX to a poly(ethylene oxide)-poly(aspartic acid) block copolymer.154 This
class of polymers is relatively non-toxic and may biodegrade through hydrolysis and/or
enzymatic degradation, though the extent of biodegradability remains to be established.150

1.6

PoIy(ester amide)s

PEAs are a class of polymers characterized by both amide and ester bonds in the
polymer backbone. PEAs emulate poly(esters) in that they offer a degree of control over
both the mechanical and thermal properties as well as their rates of degradation. The
incorporation of amide linkages increases the ability to tune the chemical and physical
properties and along with the esters allow for the possibility of enzymatic degradation.
PEAs offer a variety of advantages over traditional systems such as poly(glycolic acid) or
poly (lactic acid) as these tend to produce potentially harmful acidic byproducts. Although
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- the glycolic and lactic acids generated during the hydrolysis of these traditionally used
polymers are present in natural human metabolic pathways, a large accumulation of these
acidic species has been demonstrated to result in tissue inflammation.155,156 The
susceptibility of the poly(ester amide)s to enzymatic degradation should enhance surface
degradation, thereby limiting the possibility of a large accumulation of acidic species in
tissues.

Conversely, the commonly used poly(amino acid)s require relatively unstable

and expensive N-carboxyanhydride monomers for synthesis

and have been found to be

immunogenic under some circumstances.159
While there are several classes of PEAs, the PEAs derived from a-amino acids,
diols, and diacids (Figure 1.2) are of particular interest for the current work, as they have
been demonstrated to undergo hydrolytic and enzymatic degradation at physiological
pH160 and the monomer components of the polymer can be chosen from metabolic
intermediates (natural amino acids and diacids) allowing for the degradation products to
also be non-toxic. In addition, by intelligent design of the backbone, the polymer’s
chemical functionality and properties including solubility, crystallinity, biocompatibility,
and degradation rate can be readily tuned.161 Finally, traditional systems tend to be
hampered by a lack of functional handles.1 These PEAs offer a multitude of avenues to
introduce functionality into the polymer backbone via the incorporation of amino acids
with side chain functional groups.160;161 For example, the pendant functional groups on
lysine or aspartic acid units offer the means to covalently attach drugs, targeting moieties,
or other functional molecules into the PEA.
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Amino
acid

Diol

Diacid

Figure 1.2: General structure of the poly(ester amide).
R1 is generally linear aliphatic or aromatic, R2 is the side chain of an amino acid
and R3 is generally linear aliphatic

Although poly(ester amide)s have appeared in the literature as early as the
1960s162,163 for use as model systems for proteins, it is only until recently that their full
utility has been realized. In order to exploit this utility, a variety of PEAs, with varying
monomer units and hence different properties have been synthesized. To date, PEAs have
been synthesized containing alanine,160’161 phenylalanine,160’161’164 leucine,165 aspartic
acid,161 lysine,157’160 serine,166 and arginine.167' 169 Unsaturated PEAs have also been
synthesized mainly through the use of allyglycine,170-172 fumaric acid,173 and maleic
acid.174’175
Recently, the incorporation of functional groups along the backbone of PEAs
using a-amino acids has become an important area of research. For example, Jokhadze et
al. formed a benzyl ester to protect the carboxylic acid group of lysine and performed a
solution polycondensation using the a and e amino groups as the diamine.

Following

the polymerization, the lysine benzyl ester was selectively cleaved via hydrogenolysis
yielding pendant carboxylic acid groups. These free carboxylic acids were further
functionalized with 4-amino-2,2,6,6-tetramethylpiperidine-l-oxy (TAM), a biomedically
useful cell growth inhibitor.
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Building upon the work of Jokhadze et al., Guan et al. also used a benzyl ester
which

was

hydrogenated

to , yield

a

pendant

carboxylic

acid;

however,

dimethylolpropionic acid, a diamine derived from hexanediol and glycine, was
conjugated instead.

177

Our group in collaboration with the Mequanint group at the University of Western
Ontario, recently developed synthetic procedures where the protected, functional amino
acids carboxybenzyl-lysine-(t-butoxycarbonyl)-OH160 or carboxybenzyl-aspartic acid-(tbutyl ester)-OH161 were converted into diamine-based polymerization monomers through
N,N'-Dicyclohexylcarbodiimide (DGC) couplings with butanediol. These monomers
were then combined with other monomers of varying structures in' solution based
polymerization methods to demonstrate the synthetic versatility of the method and to
arrive at polymers with varying physical properties. Recently, we also compared this
solution phase method to an interfacial polycondensation and found that higher molecular
weights were produced with the interfacial method.

In addition, interfacial

polymerization is generally more attractive than solution polycondensation because it is
\

faster and less influenced by impurities.178
Alternately, Pang and Chu have recently incorporated DL-2-allylglycine as the
functional amino acid into a solution polycondensation. The utility of DL-2-allylglycine
stems from the double bond that allowed the authors to further derivatize the polymer.
For example, reaction of the alkene with 3-mercaptopropionic acid was shown to yield a
pendant carboxylic acid, while 2-aminoethanethiol hydrochloride produced a pendant
amine and sodium-3-mercapto-l-propanesulfonate yielded a pendant sulfonate group.
The authors also claim that if not derivatized, the double bond could also be crosslinked
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- with PEG diacrylate to produce a hydrogel. 1 7 9 While attractive, the DL-2-allylglycine
monomer is quite expensive to prepare and results in some loss of the biomimicry of the
polymers as it is not a natural amino acid.

1.6.1

Biomedical Uses ofP oly (esteramide)s

Jokhadze et al. used PEAs to immobilize TAM, which is a nitric oxide mimic
shown to suppress the proliferation of human smooth muscle cells in vitro.

i n<r

The

suppression effect is ideal for the mediation of certain clinical conditions such as
restenosis of vascular stents.

The physical and biological properties of the polymers, as

well as the ability to conjugate bioactive molecules, make PEAs a very attractive option
for biomaterials.

-

In recent work, Knight et al. have shown that certain PEAs may be effective
tissue engineering scaffolds as the glass transition temperatures are below or within the
physiological range, ensuring proper pliability. Human coronary artery smooth muscle
cell attachment and spreading was observed up to 7 days of culture and immunostaining
of cells illustrated strong vinculin expression on all surfaces; however, smooth muscle aactin expression was not abundant, suggesting a proliferative, rather than a contractile,
smooth muscle cell phenotype. These results suggest that PEAs could be used in vascular
tissue engineering applications.
Del Valle et al.'investigated the use of a biodegradable PEA to create a drug
delivery scaffold. The scaffold was made through a compression-molding/particulateleaching method and showed good cell viability and supported cell growth. Ibuprofen
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- was loaded onto the scaffold and was found to release quickly. The release rate could be
slowed by the addition of PCL to the immersion medium allowing for control over the
release rate.181
Chu et al. have shown that hydrogels based on PEAs can be used as sustained
release systems. 1 7 1 ’ 1 8 2 ’1 8 3 In other work, PEAs have been used by Liu et al. as non-viral
gene delivery vehicles with a high plasmid deoxyribonucleic acid binding capacity.

In

addition, Defife et al. has found that PEA coated cardiovascular stents promote a more
natural healing response.

1

85 1 fi/i
’

Currently, there are very few examples of particle-based drug delivery systems
comprising PEAs. For example, Guo et al. developed microspheres of amino acid based
PEAs via an oil in water emulsion/solvent evaporation technique. 5 3 The effects of PEA
polymer concentration, PVA emulsifier concentration, and the homogenizer speed on the
size and morphology of final PEA microspheres were examined by analyzing their
scanning electron microscopy (SEM) images. It was found that a low PEA concentration,
a high PVA concentration, and a high homogenizer speed were the optimal conditions for
\
obtaining particles one micrometer in diameter. The biodegradation behaviours of these
microspheres were investigated and it was found that the degradation was largely based
on surface erosion. The particles were also capable of encapsulating paclitaxel with high
efficiency, approximately 95%; however, the particles are microsized, meaning they will
be readily cleared by the RES and the lack of functional handles limits the possible uses
of this system. While PEA based NP delivery systems of antibiotics and paclitaxel have
been reported , 1 8 7 ’ 1 8 8 currently, to the best of our knowledge, there are no micellar drug
carriers based on PEAs.
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1.7

Thesis Goals

Having developed a synthetic method for the incorporation of pendant amine and
carboxylic acid functional handles onto the PEA backbone , 1 5 7 ’ 1 6 0 ’ 1 6 1 and with the
Mequanint group, demonstrated the potential utility of these PEAs in vascular tissue
engineering applications , 1 5 7 the goal of this thesis was to explore the potential utility of
these functional handles in the development of enhanced drug delivery systems based on
PEAs. The thesis involves two different, but related applications of these functional
groups.
In Chapter 2, the use of pendant carboxylic acid groups of aspartic-acid moieties
along the PEA backbone to covalently immobilize drug molecules by degradable ester
linkages is explored (Figure 1.3a). The aim of this work is to address the burst release
problem commonly observed for polymer NP based drug delivery systems as described
above . 1 3 0 ,1 3 1 After synthesizing a model drug-PEA conjugate complex, the resulting
conjugate is converted into surfactant-stabilized NPs via an oil in water emulsion. Over
time, the ester bond, between the polymer and the drug will slowly hydrolyze, releasing
the drug. The appeal of this system is that the release of the drug will be limited by the
hydrolysis kinetics, not diffusion. Therefore, the release will be more controlled 5 6 and the
system will be less likely to release its payload before accumulating in the target tissue.

63

In addition, unlike the previously described PEA particles , 5 5 ’1 8 9 the size of these particles
is optimized to be less than

2 0 0

nm in diameter, thus potentially allowing them to

circulate in the vascular without rapid removal by the reticuloendothelial system. ,
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Figure 1.3: Two Approaches to PEA Drug Delivery Vehicles.
a) Polymer nanoparticles with covalently bound drugs that will not exhibit a burst release
b) PEO grafted PEAs self assemblies that can physically entrap drugs

While promising for drug delivery applications, in the course of this thesis
research, some limitations to the surfactant stabilized NPs described above were
encountered. For example, large quantities of PVA were required to obtain nanosized
particles. While PVA has been approved by the Food and Drug Administration for many
applications, coating of the NP surface may mask the properties of the PEA, slow the
particle’s biodegradation, and prevent the conjugation of targeting moieties to the PEA’s
pendant functional groups. In addition, it was found that some model drugs interacted
with the PVA surfactant, resulting in their non-specific binding to the particle surface. To
address these issues, as described in Chapter 3, amphiphilic properties can be imparted to
the PEA itself through the conjugation of hydrophilic PEO to the pendant lysine moieties
of a hydrophobic PEA backbone (Figure 1.3b). The PEO-PEA graft copolymers are then
shown to self-assemble into micelles that can encapsulate model hydrophobic drugs in
the micelle interior. These micelles do not require additional surfactant loading and the
assemblies are smaller, which may lead to an extended circulation time in vivo.2,6'9'11
■)
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Although outside the scope of this thesis, the ultimate goal would be to combine
both systems. For, example, drug molecules could be covalently bound to the PEA
backbone in addition to the PEO, allowing for self-assembly into micelles as well as a
highly controlled release profile. Furthermore, in addition to acting as hydrophilic chains
to introduce amphiphilic properties to the PEA, the PEO can also potentially function as a
linker for the addition of targeting ligands. Towards this longer term goal, this thesis

drug molecules to illustrate the concepts.
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Chapter Two:
Covalent Immobilization of Drug Molecules in
Poly(ester amide) Nanoparticles
2.1

Introduction

Nanotechnology pertains to synthetic, engineerable objects that are on the order of
1 0 0

nm in one dimension, leading to unique properties due to the material's large surface

area to volume ratio and its nanoscopic size. ’ One of the most important applications of
these unique properties is the creation of nanoparticle (NP) based drug delivery vectors
that can overcome a host of pharmaceutical and physiological barriers in order to enhance
the delivery of drug molecules to a biological target. Towards this end, a wide range of
polymer based nanoparticles have been developed. Perhaps the most common example is
poly(lactic-co-glycolic acid) (PLGA) which has been shown to encapsulate anti-cancer
agents (paclitaxel and doxorubicin ) , 3 ’4 sex hormones (estradiol) , 5 ’6 anti-leishmanial agents
(amphotericin B ) , 7 immunosuppressants (cyclosporine ) 8 and hyperlipidemia treatments
(atorvastatin, sold under the name Lipitor ) . 9 All of these NP systems displayed higher
bioactivity relative to free drug as well as an increased in vivo circulation time. Other
examples of nanoscale, polymeric delivery systems include chitosan to deliver
ammonium

glycyrrhizinate , 1 0

poly(caprolactone)
methoxycinnamate . 1 6

(PCL)

to

proteins , 11
deliver

insulin , 1 2

tamoxifen , 1 4

and

doxorubicin 1 3

mixnoxidil, 1 5

and

or
octyl
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Overall, polymer nanoparticles have been successful in enhancing the effective
solubility of hydrophobic drugs ’ ’ , preventing enzymatic degradation , and avoiding
sequestration by phagocytes of the reticuloendothelial system (RES ) . 2 0 ,2 1 Despite their
promise, there still remains a series of challenges for polymer nanoparticles, one of which
is the commonly observed burst release effect. ’ It occurs when a large percentage of
the drug is released in a short time period and is in most cases undesirable. The burst
release tends to be unpredictable, may induce local toxicity, and may result in a loss of
activity if the drug has a short half-life . 2 2 In addition, releasing too much drug at once is
economically and therapeutically wasteful, and the shortened release profile requires
more frequent dosing. In some cases, such as flavours in the food industry or pulsatile
delivery devices, burst may be desirable, but even in these cases, the amount of drug
released in the burst is relatively hard to model and control. 2 2 , 2 3
While there are relatively few examples, it has recently been demonstrated that
the covalent immobilization of drug molecules within polymer nanoparticles may be an
effective way to slow and better control their release rates . 2 4 While it has been shown that
many drug/polymer complexes display promise in vitro, in particles targeted to cancerous
tissue in vivo, covalent immobilization may greatly increase therapeutic efficacy since the
drug is not released prematurely under physiological conditions. 2 5
Overall, one of the key properties desirable in a polymer nanoparticle delivery
system is the biodegradability of the polymer. While many different biodegradable
polymers are potentially available, in recent years poly(ester amide)s (PEAs) based on
amino acids, diols, and dicarboxylic acids have emerged as promising materials for a
wide range of biomedical applications such as drug eluting stents , 2 6 ’2 7 tissue engineering
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- scaffolds, 2 8 and drug delivery vehicles such as scaffolds , 2 9 hydrogels , 3 0 ' 3 2 and
microspheres . 3 3 ’3 4 Currently there are only two examples of drug delivery particles based
on this class of PEAs , 3 3 , 3 4 but these report particle diameters of approximately 1 pm and
4.5 pm respectively. It has been shown that particles with a diameter greater than 200 nm
are easily removed by the reticuloendothelial system, while smaller particles will
circulate longer in the body. '
2 0 0

It has also been shown that particles in the range of 2-

nm tend to accumulate in cancerous tissue due to the enhanced permeability and

retention effect. '

Therefore, the NP systems described in previous work may not be

useful for many drug delivery applications such as tumour targeting. Recently, our group
has reported versatile approaches for the incorporation of pendant functional groups into
PEA backbones by the copolymerization of protected aspartic acid or lysine moieties
with other monomers. Here we explore the use of these pendant functional groups for the
covalent immobilization of drug molecules in order to develop enhanced drug delivery
nanoparticle systems based on PEAs (Figure 2.1). In addition, we report for the first time
PEA nanoparticles with diameters less than 200 nm that could be able to circulate in the
blood.

^
^
VB M P/—

Drug
Cleavable Ester Bonds
Hydrophobic Poly(ester amide) Core

^

Hydrophilic Poly(vinyl alcohol) Shell

Figure 2.1: Diagram of covalently immobilized PEA drug delivery system.
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2.2
2.2.1

Results and Discussion
Synthesis o f Polymers without Pendant Functional Groups

In order to optimize the nanoparticle preparation procedure, polymers without
functional handles, 1-4, were used as they can be more easily synthesized relative to the
analogous polymers containing functional handles (Figure 2.2). These polymers were
prepared by the previously reported methods 2 8 , 3 8 and were characterized by !H nuclear
magnetic resonance (NMR) spectroscopy as well as gel permeation chromatography
(GPC). The characterization data agreed with those previously reported.

Figure 2.2: Structures of PEAs without pendant functional groups.
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2.2.2

Optimization o f the Nanoparticle Preparation Procedure

With polymers in hand, a procedure to form nanoparticles was required. An oil in
water solvent evaporation method was chosen based on the solubility of PEAs, its general
effectiveness, and its ease of use.19 As seen in Figure 2.3, the procedure involves the
formation of an emulsion between an aqueous surfactant and the polymer of interest in a
volatile organic solvent. As the solvent evaporates, the polymer forms nanosized particles
that remain suspended in the aqueous phase due to the presence of a surfactant shell.
Using procedures for similar systems found in literature, a procedure for PEAs was
optimized to produce the smallest particles with the narrowest polydispersities.19'39 As
described above, the goal was to obtain particles with diameters less than 200 nm.

S o n ic a tio n

S u r fa c ta n t in
w a te r a n d PEA
in c h lo r o fo r m

E va p o ra tio n

“Oil in W ater”
E m u lsio n

N a n o p a rticle
d is p e r s io n
in w ater

Figure 2.3: General oil in water nanoparticle formation procedure.

The system was designed using poly(vinyl alcohol) (PVA) as a surfactant,
chloroform as a volatile organic solvent and a sonication probe to produce the emulsion.
Parameters under investigation included surfactant concentration, polymer concentration,
oil/water volume ratio, probe height, and sonication time. Dialysis, ultrafiltration and
centrifugation were evaluated for the removal of free PVA and ultrafiltration was chosen
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as the preferred method as dialysis membranes did not have a high enough molecular
f
weight cut-off and our centrifuge was not powerful enough to isolate the NPs since the
particles produced were much smaller than those previously reported . 3 3 , 3 4
To produce smaller particles several parameters of the NP formation procedure
were tuned. First, the concentration of PEA in the oil phase was varied while keeping the
concentration of surfactant and oil/water ratio constant. As shown in Figure 2.4, it was
found that decreasing the concentration of the oil phase decreased particle diameter.
However, there was a limit where a too dilute solution failed to produce particles. It was
found that 5 mg/mL was an optimal concentration for minimum diameter.
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Figure 2.4: An investigation of the effect of [PEA] on particle diameter shows that the
particles are smaller at lower [PEA]. However, at very low concentrations no particles are
formed.
Parameters: OilAVater Ratio = 1/10, [PVA] = 20 mg/mL, polymer 4

42
Next, the concentration of surfactant was varied while the concentration of PEA
and oil/water ratio was held constant. As shown in Figure 2.5, it was found that
increasing the concentration of PVA decreased particle diameter; however, the
concentration is limited by the aqueous solubility. Therefore, a saturated solution of 20
mg/mL was used in the optimum procedure.

'c
c
;c
40)
-*
0)
p
CO
5

400
350
300
250
200
150
100
50
0

0

5

10

15

20

25

[P VA ] (mg/mL)

Figure 2.5: An investigation of the effect of [PVA] on particle diameter shows that as the
[PVA] is increased, the particle size decreases.
Parameters: OilAVater Ratio = 1/10, [PEA] = 25 mg/mL, polymer 4
Note: aqueous solubility limits the maximum [PVA]

Finally, the oil/water volume ratio was varied while keeping the concentration of
PVA and PEA constant. As shown in Figure 2.6, it was found that the minimum diameter
occurred at a ratio of 0.05.
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Figure 2.6: An investigation of the effect of oil/water ratio on particle diameter does not
show an effect on particle size. Note that particles do not form at higher ratios.
Parameters: [PVA] = 11.5 mg/mL, [PEA] = 25 mg/mL, polymer 4

Overall, it was found that the optimum procedure involved 20 mg/mL of PVA, 5
mg/mL of PEA, and an oil/water volume ratio of 0.05. The probe height was set at 1.5 cm
and the volume of water used was 10 mL. According to dynamic light scattering (DLS),
the diameter of particles produced was approximately 120 nm (Figure 2.7) which is an
order of magnitude smaller than previously reported . 3 3 The PDI of the particles was also
very low, only 0.041, indicating the particles are nearly uniform in size, a necessity if the
system will be used clinically. The procedure was repeated for a variety of PEAs, all
producing similar results: Therefore, the general procedure is versatile with respect to
polymer composition and can be extended to other systems.
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Figure 2.7: DLS trace of NP from polymer

6

. Note that the x axis is in a logarithmic

scale.
D = 118.4 nm ,PD I = 0.041

2.2.3

Synthesis o f Polymers with Pendant Functional Groups

Functional polymers were synthesized according to published procedures . 4 0 PE As
of various diols, diacids, and amino acids were synthesized in order to assess a range of
possible applications for the polymers. The materials were characterized by !H NMR and
GPC and four unique PEAs, polymers 5-8, shown in Figure 2.8, were isolated for testing
as potential drug delivery vehicles. Polymers 5 and

6

were made using a solution

polymerization technique due to the short chain length of succinic acid while polymers 7
and

8

which used sebacic acid were made using an interfacial technique. Both methods

produce random copolymers with repeating ester and amide bonds.
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Figure 2.8: Structures of functionalized PEAs. Each PEA contains approximately 10
mol% of the aspartic acid unit randomly distributed throughout the polymer backbone.

2.2.4

Preparation o f Nanoparticles Containing Covalently Immobilized Model Drug

Alcohol functionalized Rhodamine B was used as a model drug in order to assess
the loading ability of the nanoparticles. This Rhodamine B derivative, shown in Figure
2.9, is highly absorbent and fluorescent, making it an ideal model for a drug molecule.
!

.

.

.

The dye was bonded to the aspartic acid using dicyclohexylcarbodiimide (DCC) to form
a hydrolyzable ester linkage prior to particle formation. The dye/polymer complex was
characterized by ultraviolet-visible (UY-Vis) spectroscopy prior to particle formation,
and then formed into nanoparticles using the aforementioned procedure. Figure 2.10
displays the DLS results for the resulting nanoparticles. The average diameter remains

}
t

■
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the same when compared to NPs without dye, but the PDI increases. The increase in
polydispersity is attributed to 7c-stacking of the dye affecting the emulsification process. It
is predicted that the increase in PDI can be mitigated by conjugate choice.

HO

Figure 2.9: Structure of the chosen model drug, an alcohol functionalized Rhodamine B
derivative.

Figure 2.10: DLS trace of NP formed from dye-conjugated polymer 6 . Note that the x
axis is in a logarithmic scale.
D = 116.4 nm, PDI = 0.261
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Preliminary degradation studies were performed on a series of NPs from the
different functional polymers having covalently immobilized dye to determine the one
with the best degradation kinetics. As shown in Figure 2.11, the release rate can be
engineered by monomer choice, creating a family of PEA drug delivery vehicles with
varying pharmacokinetics. Polymer

6

was chosen for further study as it had the fastest

release and had much better solubility than polymer 5, facilitating synthesis and
expanding the list of candidates the system could deliver. Interestingly, the nanoparticles
composed of the more hydrophobic polymers only release negligible quantities of drug
over the time scale of this experiment, presumably due to poor water access to the
nanoparticle core, resulting in very slow ester hydrolysis rates. However, it should also be
noted that the polymer molecular weights vary with monomer selection and the lack of
release can possibly be attributed to molecular weight effects rather than increased
hydrophobicity. Polymers 7 and

8

, which used sebacic acid and the interfacial

polymerization method, have significantly higher molecular weights (Mw= 32000 and
101000 g/mol respectively) than polymers 5 and 6 , which use succinic acid and a solution
method (Mw= 7700 and 20000 g/mol respectively). However, as it is not easy to control
the molecular weight in these polymerizations, it is difficult to confirm this.
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Figure 2.11: Effect of polymer choice on release rates of covalently immobilized
Rhodamine.

2.2.5

Characterization and Application o f the Nanoparticles

Through UV-Vis measurements it was found that 41% of the pendant aspartic
acid handles on polymer

6

were conjugated with the Rhodamine derivative,

corresponding to a drug loading of 7% (mass of dye/mass of nanoparticles). In order to
compare how effectively the immobilization reduces the rate of drug release a control
with physically encapsulated Rhodamine was made. Rather than immobilizing the
Rhodamine on the polymer, the model drug was added to the organic phase during NP
formation where it will accumulate in the NP center. The driving force for forming a
concentration gradient is lowering the overall energy of the system by minimizing
unfavorable polar/non-polar interactions between the Rhodamine and water and
increasing favorable non-polar/non-polar interactions with the polymer core. In this case,
there is no covalent bond anchoring the model drug to the NP, so the release profile may
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be diffusional and display a burst. Release studies on the physically encapsulated
control were done in pH 7.4 phosphate buffer at 37 °C and compared to the novel
covalently immobilized PEA system under the same conditions. As seen in Figure 2.12,
the physically encapsulated system provided complete release of Rhodamine in about 9
hours while the covalently immobilized one reached only about

1 0

% release over the

same time frame. Monitoring the covalent release for a longer time frame showed that the
covalently immobilized dye took approximately 20 days to reach 90% release (Figure
2.13). This result shows the utility of the PEA’s functional handles for covalent
immobilization and the system’s ability to control release rates. The model drug was
released in a time frame that is considered therapeutically relevant , 2 2 ’3 0 , 4 1 ' 4 4 making it a
promising candidate for future applications.
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Figure 2.12: Comparing the release of physically encapsulated vs. covalently
immobilized Rhodamine. The covalently immobilized drug released much more slowly
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- than the non-covalently immobilized drug, indicating that hydrolysis rather than
diffusion is the rate limiting step in the drug release.
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Figure 2.13: Long time frame release of covalently immobilized Rhodamine.

When trying to market a delivery system, it is highly desired that the formulation
can be packaged and transported in a solid state and reconstituted prior to injection since
the water in a dispersion takes up far more volume and is much heavier. There are also
degradation and storage issues as powders have a far longer shelf life than dispersions
and may not require refrigeration. In order to test the practicality of this PEA delivery
system, NPs were formed, lyophilized and reconstituted. Through DLS measurements it
was found that there was no change in NP diameter upon reconstitution (Figure 2.14).
Hydrodynamic diameter and polydispersity were actually slightly smaller upon
reconstitution, probably because the DLS measurement was taken directly after
sonication while the pre-lyophilization measurement was done after only stirring.
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Figure 2.14: DLS trace showing no change in particle diameter after lyophilization and
reconstitution. Note that the x axis is in a logarithmic scale.

In order to assess the toxicity o f the NP, an MTT assay was run. In an MTT assay,
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is reduced to a
purple formazan by living cells. This formazan is insoluble so a solubilizing solution is
used to create a solution that can be measured using UV-Vis spectroscopy. Since the
reduction is done by living cells, the absorbance of formazan will be proportional to the
cell viability . 4 5 Over the course of 48 hours, it was found that at concentrations up to 2
mg/mL, the highest concentration investigated, the NP exhibited very low toxicity
(Figure 2.15). Rough calculations predict that a therapeutically useful delivery system
based on PEA NPs and dactinomycin would have a NP concentration between 0.125 and
0.25 mg/mL. This calculation assumed no change in drug loading and administration
through an IV.
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Figure 2.15: MTT assay displaying low PEA NP toxicity.

2.3

Conclusions

By employing a more powerful sonication method and running a series of
optimization experiments, the procedure for creating PEA nanoparticles was significantly
improved relative to previous reports , 3 3 resulting in the formation of nanoparticles of
appropriate size to circulate in vivo. In addition, our synthetic approach for the
preparation of PEAs containing pendant carboxylic acids was used to prepare
nanoparticles from these functional polymers. An alcohol functionalized Rhodamine B
derivative was chosen as a model drug and was coupled to the PEA prior to NP synthesis.
It was found that the covalently immobilized model drug was released far slower than a
traditional physically encapsulated control. In addition, this system is potentially capable
of delivering a wide range of therapeutics, can be dried and reconstituted for convenient
storage and transport, and the remaining pendant carboxylic acids can potentially be
further conjugated with targeting ligands or dyes for imaging.

This covalently
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immobilized nanocarrier displays great promise for applications in sustained release
drug delivery.

2 .4

Experim ental

2.4.0

General Procedure and Methods

Solvents were purchased from Caledon Labs (Georgetown, ON). All other
chemicals were purchased from Sigma Aldrich (Milwaukee, WI) or Alfa Aesar (Ward
Hill, MA). Unless noted otherwise, all chemicals were used as received. Anhydrous
dichloromethane and A.TV-dimethylacetamide (DMA) were distilled over CaH 2 .
Tetrahydrofuran (THF) was obtained from a solvent purification system. Infrared (IR)
spectra were obtained using

a Bruker Tensor 27 instrument as films from

dichloromethane on NaCl plates. *H NMR spectra were obtained at 400 MHz on a Varian
Mercury 400 Spectrometer. Chemical shifts are reported in ppm and are calibrated
against residual solvent signals of CDCI3 (57.27) or dimethylsulfoxide (DM SO-^)
(52.54). All coupling constants (J) are reported in Hz. Gel permeation chromatography
data were obtained using a Waters 2695 separations module equipped with a Waters 2414
refractive index detector (Waters Limited, Mississauga, ON) and two PLgel 5 pm mixedD (300 mm x 7.5 mm) columns connected in series (Varian Canada). Samples (5 mg/mL)
dissolved in the eluent, which comprised 10 mM LiBr and 1% (v/v) NEt3 in DMF at 85
°C were injected (100 pL) at a flow rate of 1 mL/min and calibrated against either
poly (styrene) or poly(ethylene glycol) standards. Molecular weights are reported in
grams/mol (g/mol).
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2.4.1

Procedure fo r Solution Polymerizations o f Poly (ester amide)s without Pendant
Functional Groups

2.4.1.1

• .’ ! •

Synthesis of Polymer 1

A di-p-nitrophenyl succinate monomer (1.5 g, 3.3 mmol, 1.0 equiv.) and a di-ptoluenesulfonic acid salt monomer from alanine and octanediol (2.0 g, 3.3 mmol, 1.0
equiv.) were combined in a round bottom flask, evacuated and purged with argon.
Distilled DMA (4.0 mL) was added to these monomers and the resulting mixture was
heated to 60°C. Triethylamine (1.0 mL, 7.3 mmol, 2.2 equiv.) was then added dropwise
to the solution and the temperature was raised to 70°C.

The reaction mixture was

maintained at this temperature for 48 h. The solution was then precipitated in cold ethyl
acetate (250 mL) and further purified through Soxhlet extraction with ethyl acetate for 48
h to provide pure polymer 1. Yield: 69%. Spectral data agreed with that previously
reported.40 GPC: Mn = 29000, Mw = 45000, PDI =1.7.

2.4.2

Procedure fo r Interfacial Polymerizations o f Poly(ester amide)s without Pendant
Functional Groups

2.4.2.1

Synthesis of Polymer 2

Sebacoyl chloride (1.1 mL, 5.0 mmol, 1.0 equiv.) was added to anhydrous
dichloromethane (30 mL), and added dropwise over 30 min to an aqueous solution (30
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■ mL) containing a di-p-toluenesulfonic acid salt monomer from alanine and octanediol
(3.2 g, 5.0 mmol, 1.0 equiv.) and sodium carbonate (1.1 g, 10 mmol, 2.0 equiv.) and
allowed to react for 12 h. Upon completion of the reaction, the solvent was removed in
vacuo.

The polymer was then washed with water prior to purification via Soxhlet

extraction with ethyl acetate for 48 h and dried in vacuo yielding polymer 2. Yield:

6 8

%.

Spectral data agreed with those previously reported . 2 8 GPC: Mn = 45000, Mw = 63000,
PDI =1.38.

■'■■■: . .

2.4.2.2

Synthesis of Polymer 3

■

\

The same procedure for preparing polymer 2 was used except a di-ptoluenesulfonic acid salt monomer from phenylalanine and butanediol (3.6 g, 5.0 mmol,
1.0 equiv.) was used instead. Yield: 78%. Spectral data agreed with those previously
reported . 2 8 GPC: Mn = 63000, Mw = 168000, PDI = 2.65.

2.4.2.3

Synthesis of Polymer 4

The same procedure for preparing polymer 2 was used except di-ptoluenesulfonic acid salt monomer from phenylalanine and octanediol (3.9 g, 5.0 mmol,
A

1.0 equiv.) was used instead. Yield: 60%. Spectral data agreed with those previously
reported . 2 8 GPC: Mn = 63000, Mw = 130000, PDI = 2.14.

.
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2.4.3

Procedure fo r Solution Polymerizations o f Functional Poly(ester amide)s

2.4.3.1

Synthesis of Polymer 5

A di-p-nitrophenyl succinate monomer (1.05 g, 2.9 mmol, 1.0 equiv.), a di-ptoluenesulfonic acid salt monomer from alanine and octanediol (1.66 g, 2.6 mmol, 0.9
equiv.), and a hydrogenated Asp(OtBu)-butanediol monomer (0.13 g, 0.29 mmol, 0.1
equiv) were combined in a round bottom flask, evacuated and purged with argon.
Distilled DMA (5.0 mL) was added to these monomers and the resulting mixture was
heated to 60°C. Distilled triethylamine (0.9 mL, 6.4 mmol, 2.2 equiv.) was then added
dropwise to the solution and the temperature was raised to 70°C. The reaction mixture
was maintained at this temperature for 48 h. The solution was then precipitated in cold
ethyl acetate (250 mL) and collected.: The crude product was redissolved in DMF and
dialyzed for at least

8

h twice. The solvent was removed in vacuo before dissolution in 4

mL of 1:1 trifluoroacetic acidrdichloromethane. This solution was stirred for 2 h in a
flame dried flask under an argon atmosphere. The solvent was removed under a stream
of air with 3 washes of 15 mL of toluene to introduce an azeotrope. Residual solvent was
removed in vacuo resulting in a brown solid, polymer 5.

Yield: 71%. Spectral data

agreed with those previously reported . 4 0 GPC: Mn = 6600, Mw = 7700, PDI =1.17.

2.4.3.2

Synthesis of Polymer 6

The same procedure as polymer 5 was followed except that a di-p-toluenesulfonic
acid salt monomer from phenylalanine and butanediol (1.8 g, 2.6 mmol, 0.9 equiv.) was

57
- used and after the reaction, the solution was diluted with dichloromethane and washed
with 1 M KHSO4 (2 x 75 mL) followed by 10% Na 2 CC>3 (3 x 75 mL). The organic phase
was dried over MgSO.*, filtered before trifluoroacetic acid deprotection. Yield: 62%.
Spectral data agreed with those previously reported . 4 0 GPC: Mn = 15000, Mw = 20000,
PDI = 1.33

2.4.4
2.4.4.1

Procedure fo r Interfacial Polymerizations o f Functional Poly (ester amide )s
Synthesis of Polymer 7

A di-p-toluenesulfonic acid salt monomer from alanine and octanediol (2.3 g, 3.6
mmol, 0.9 equiv.) and sodium carbonate (0.85 g, 8.0 mmol, 2.0 equiv.) were dissolved in
distilled water (30 mL). A diamine made from deprotected aspartic acid and butanediol
(0.17 g, 0.4 mmol, 0.1 equiv.) was dissolved in dichloromethane (15 mL) and added to
the aqueous phase and allowed to mix for 30 min. Sebacoyl chloride (1.0 mL, 4.0 mmol,
1.0 equiv.) diluted in anhydrous dichloromethane (15 mL), was added dropwise over 30
min to the biphasic solution and was allowed to react for 24 h. Upon completion of the
reaction, solvent was removed in vacuo.

The functional poly(ester amide) was

redissolved in DMF permitting filtration of the insoluble salts. The filtrate was then
dialyzed against DMF for at least

8

h twice. The solvent was removed in vacuo before

dissolution in 4 mL of 1:1 trifluoroacetic acid:dichloromethane. This solution was stirred
for 2 h in a flame dried flask under an argon atmosphere. The solvent was removed
under a stream of air with 3 washes of 15 mL of toluene to introduce an azeotrope.
Residual solvent was removed m vacuo resulting in a brown solid, polymer 7.

Yield:

58
-

8 6

% .-‘H NMR (400 MHz, CDC13): 5 6.17 (d, 2H, J = 7.4, -N/f-CO-), 4.59 (m, 2H, -

CaH), 4.18-4.08 (m, 4H, -C (0 )0-C tf2-), 2.23-2.17 (m, 4H, -NH-C(0)-Ctf2-), 1.69-1.58
(m, 8 H, -C (0)0-C H 2 -C/f2-, -NH-C(0)-CH 2 -Ctf2-), 1.43 (s, 1.8H, -C (0)0-C (C H 3)3, 1.401.27 (m, 22H, -CaH-CH3, -C (0)0-C H 2 -GH2 -(CH2)4-, -NH-C(0)-CH 2 -CH 2 -(C//2)4-).
GPC: Mn = 18000, Mw = 32000, PDI = 1.8.

2.4.4.2

Synthesis of Polymer 8

The same procedure for the synthesis of polymer 7 was used, except that a di-ptoluenesulfonic acid salt monomer from phenylalanine and butanediol (2.6 g, 3.6 mmol,
0.9 equiv.) was used instead. Yield: 74% 1H NMR (400 MHz, CDC13): 5 7.33-7.07 (m,
10H, Ph), 6.03 (d, 2H, J = 7.8, -NH-CO-), 4.92-4.83 (m, 2H, -CaH), 4.17-3.98 (m, 4H, C (0)0-C H 2-), 3.17-3.03 (m, 4H, -CaH-CH2-Ph), 2.16 (t, 4H, J = 7.4, -NH-C(0)-CH2-),
1.66-1.50 (m,

8

H, -C(0)0-CH2-CH2-, -NH-C(0)-CH2-CH2-), 1.43 (s, 1.8H, -C (0)0-

C(CH 3 ) 3 1.33-1.19 (m,

8

H, -NH-C(0)-CH2-CH2-(CH2-)4. GPC: Mn = 43000, Mw =

101000, PDI = 2.4.

2.4.5

General Procedure fo r Rhodamine Derivative Coupling to PEAs

2.4.5.T

Rhodamine Dye Coupling to Polymer 5

Polymer 5 (0.01 g, 27 pmol), DPTS (0.006 g, 20.5 pmol, 5 equiv. relative to the
number of pendant carboxylic acids), DMAP (0.003 g, 20.5 pmol, 5 equiv. relative to the
number of pendant carboxylic acids) and the Rhodamine derivative (0.021g, 41.0 pmol,
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1 0

equiv. relative to the number of pendant carboxylic acids) were combined in a round

bottom flask, evacuated and purged with argon. Distilled CH 2 CI2 (4 mL) was added and
the mixture was allowed to stir. Upon complete dissolution, DCC (0.017 g, 82.0 pmol, 20
equiv. relative to the number of pendant carboxylic acids) was added and the solution
was covered in aluminum foil and allowed to stir overnight. The solvent was removed in
vacuo and the dark pink product was dialyzed against DMF with molecular weight cut off
(MWCO) 12-14 kg/mol for 24 hours with changing of the dialysate every

8

hours

(dialysis beaker covered in aluminum foil to prevent photo-bleaching). The solvent was
removed in vacuo yielding a dark pink solid. Yield: 90%.

2.4.5.2

Rhodamine Dye Coupling to Polymer 6

The same procedure for the coupling to polymer 5 was used except polymer

6

(0.01 g, 21 pmol) was used instead. Yield: 91%.
■

2.4.5.3

•

\

Rhodamine Dye Coupling to Polymer 7

The same procedure for the coupling to polymer 5 was used except polymer 7
(0.01 g, 16 pmol) was used instead. Yield: 89%.

2.4.5.4

Rhodamine Dye Coupling to Polymer 8

The same procedure for the coupling to polymer 5 was used except polymer
(0.01 g, 18 pmol) was used instead. Yield: 87%.

8

60

2.4.6

Nanoparticle Formation Procedure

Poly(vinyl alcohol) with a MW of 33 kg/mol and 87-89% hydrolyzed (0.2 g, 6.1
pmol) was dissolved in 10 mL of distilled water with heavy sonication (but no heating as
heating would cause precipitation of polymer prior to NP formation). The chosen
polymer (5 mg) was put in a 5 dram vial and 0.5 mL of chloroform was added. Upon
dissolution, the PVA solution was added and the two phase mixture was sonicated with a
Branson Digital Sonifier. The probe tip was kept 1.5 cm from the vial bottom and the
amplitude was set to 25%. The mixture was sonicated for 2 minutes with pulses of 30
seconds on and 10 seconds off. Once sonicated, the latex was stirred overnight to remove
the chloroform. The dispersion was put in an ultrafiltration apparatus with a membrane
MWCO of 500000 g/mol. The dispersion was diluted and filtered a total of four times.

2.4.7

Determination o f Dye Loading

K

Dye coupled polymer (0.015 g) was dissolved in 2 mL of THF and 4 mL of 1 M
KOH was added. After stirring for 48 hours, while covered with aluminum foil, 0.2 mL
of the solution was removed and diluted with 2.5 mL of distilled water. UV-Vis
measurements were performed using a molar absorptivity of 76470 M ^cm '1.
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- 2.4.8

Covalently Immobilized Nanoparticle Release Study Procedure

The same nanoparticle formation procedure was followed using dye-conjugated
PEA but afterwards the dispersion was placed in a Slide-A-Lyzer dialysis cassette and
kept at 37 °C in pH 7.4 phosphate buffer. UV-Vis measurements were taken of the
internal volume and therefore the absorbance measured includes light scattering from the
particles. For every measurement, a power curve was fitted to the scattering and
subtracted from the measured data in order to decouple the absorbance. Each fitted curve
had an R 2 value of at least 0.98.

2.4.9

Physically Encapsulated Nanoparticle Release Study Procedure

The same procedure for the covalently immobilized release study was used
however non-dye-conjugated PEA was used and 0.0025 g of Rhodamine derivative was
dissolved in the organic phase prior to sonication.
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Chapter Three:
Development of Poly(ethylene oxide)-Poly(ester amide) Graft
Copolymers for Micellar Drug Delivery Vehicles

3.1

Introduction

Among the various polymer nanocarriers that have been investigated , 1 ' 4 polymer
micelles are attractive due to their ease of synthesis and their ability to be tuned . 1
Polymeric micelles are colloidal dispersions of amphiphilic polymers that can be used to
increase the solubility and bioavailability of poorly soluble drugs as well as increase the
in vivo circulation time due to nanoscale particle diameters and hydrophilic outer shells
that inhibit phagocytic and renal clearance. The extended circulation time leads to
selective tumour accumulation via the enhanced permeability and retention (EPR)
effect. 2 ' 4
One limitation of the delivery system discussed in Chapter 2 is that relatively
large amounts of poly(vinyl alcohol) (PVA) are required in order to obtain nanoparticles
(NPs) small enough to remain in circulation. While PVA is approved by the Food and
Drug Administration for many applications, coating the nanoparticle surface may mask
the properties Of the poly(ester amide) (PEA), slowing its biodegradation, and preventing
the conjugation of targeting moieties to the PEA’s pendant functional groups. In addition,
certain molecules were found to interact non-specifically with the surfactant layer, which
impeded diffusion from the nanoparticle. Finally, the PVA layer may impede diffusion
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from the nanoparticle and may increase the minimum particle diameter by increasing
external phase viscosity at higher concentrations. 5
In order to address these issues, poly(ethylene oxide) (PEO)-PEA graft
copolymers were proposed. Such graft copolymers could be prepared by the conjugation
of PEO to the pendant amine groups of PEAs previously reported by our group.

PEO

was chosen for the hydrophilic block due to its strong hydrophilic properties as well as its
capability for masking the presence of circulating foreign substances by shielding
antigenic and immunogenic epitopes as well as preventing receptor-mediated uptake by
the RES . 6 While the PEA backbone is quite hydrophobic, PEO is a well known
hydrophilic polymer and by imparting amphiphilic properties to the PEA itself, the need
for surfactant should be eliminated. The resulting copolymer should self assemble in
aqueous media into micelles in the absence of surfactant addition.
Described here is the preparation of PEO-PEA graft copolymers and the study of
their assembly into micelles. These micelles are very promising biomaterials due to their
biodegradability. Under physiological conditions, the ester bonds in the backbone can be
cleaved hydrolytically, while the amide bonds can potentially be cleaved enzymatically.7'
9

This biodegradation would ultimately result in the release of individual PEO chains that

can be readily excreted from the body. In addition, while the conjugation o f PEO would
consume some pendant amine groups of the polymer, the remainder could be used to
covalently immobilize drug molecules in order to control their release as described in
Chapter 2. In addition, while one terminus of the PEO would be conjugated to the PEA,
the other terminus could be used to conjugate bioactive moieties to target the micelles to
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- selective tissues, such as tumours. To the best of our knowledge, this work is the first
example of polymeric micelles based on PEAs.

3.2

Results and Discussion

3.2.1

Synthesis o f PEO-PEA graft copolymers

A PEA having pendant amine functional groups (Figure 3.1) was synthesized
according to the previously published method . 9 Briefly, as shown in Scheme 3.1, an
interfacial polymerization was performed using

1 .0

equivalents of sebacoyl chloride

1

,

0.90 equivalents of the phenylalanine-based diamine 2, and 0.1 equivalents of the lysinebased diamine 3. The interfacial polymerization was performed with the diamines in the
aqueous phase and the diacid chlorides in the dichloromethane organic phase. As shown
in Scheme 3.2, the BOC protecting group was removed using trifluoroacetic acid (TFA).
/• <
7

NMR spectroscopic characterization agreed with the previously published results ’ with
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PEO of molecular weights 2000 g/mol (PEO 2K) and 5000 g/mol (PEO 5K) were
selected based on the fact that in general, copolymers with hydrophilic volume fractions
greater 50% are found to form micelles, while those with lower hydrophilic volume
fractions are found to form other morphologies such as vesicles and cylinders. 1 0 The
conjugation of PEO 2K to 100% of the amines would provide a PEO weight content of
41% while the conjugation of PEO 5K to 100% of the pendant amines would provide a
weight content of 64%. The conjugation reaction conditions can be adjusted to give fine
control over the weight content of PEO in the copolymer. The conjugation reaction
required activated PEOs which were synthesized by the reaction of PEO and 4nitrophenyl chloroformate as shown in Scheme 3.3.

6 or

no2

Scheme 3.3: Activating PEO with 4-nitrophenyl chloroformate. Two PEO molecular
weights were used to make polymers

6

and 7 (n= 114 and n= 45 respectively).

Coupling the activated PEO to the PEA was performed in dichloromethane using
diisopropylethylamine (DIPEA) and 4-dimethylaminopyridine (DMAP), as shown in
Scheme 3.4. It was anticipated that the abilities of the copolymers to form micelles and
the resulting properties of the micelles, such as their size and stability, would be
determined by the degree of PEO coupling. Therefore, in order to investigate different
PEO contents, either 0.85, 1.2, or 3 equivalents of PEO 5K relative to the number of
pendant amines were used in the coupling to provide graft copolymers

8

, 9, and 10

respectively. The coupling with PEO 2K was performed using 1.2 equivalents to provide
graft copolymer

1 1

.
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Scheme 3.4: Synthesis of PEO-PEA graft copolymers. Varying the MW and loading of
PEO affords copolymer 8 through 11.

Following the evaporation of the reaction solvent, the removal of free PEO was
challenging. First, dialysis in water using a membrane with a 50000 g/mol molecular
weight cut off (MWCO) was attempted. The dialysate was changed twice a day over the
course of one week. The polymer suspension inside the dialysis bag was recovered and

s-
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- dried in vacuo. The GPC chromatograph shown in Figure 3.2, indicates that after
dialysis there is still a large amount of free PEO, as seen by the side peak at 15 minutes,
meaning this purification method was ineffective. However, it was possible to remove
this free PEO by preparative GPC as shown in Figure 3.3.

Figure 3.2: GPC trace of polymer 9 after dialysis. PEO visible as longer elution time side
peak.
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j

Figure 3.3: GPC trace of copolymer 9 after preparative GPC displaying effective

;
S

removal of PEO.

|

Following removal of the free PEO by preparative GPC, the polymers were

i

characterized by ’H NMR spectroscopy and size exclusion chromatography. The results
are summarized in Table 3.1. When 0.85 equivalents of PEO relative to the pendant
amines were used, 41% of the amine groups were functionalized with PEO based on
NMR analysis. Increasing the number of PEO equivalents to 1.2 led to an increase in the
degree of functionalization to 50%, while using 3 equivalents provided 61%
functionalization. Using PEO 2K, 1.2 equivalents provided a graft copolymer in which

j

53% of the amines were functionalized. As expected, the Mns of the polymers increased
with the degree of PEO functionalization as well as PEO MW.

j
|

j
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- Table 3.1: Effect of PEO loading on polymer
Lysine
Equivalents

PEO MW

Polym er

Mnc

S u b stitu tion 11
o f PEO a

(g /m o l)

PDI
(g/m ol)

(%)
8

0.85

5000

41

30000

1.5

9

1.2

5000

50

31000

1.6

10

3

5000

61

34300

1.2

11

1.2

2000

53

24000

1.4

a During synthesis- relative to the num ber o f lysine residues
bAccording to NMR integration
c Relative to poly(ethylene oxide)

3.2.2

Preparation o f micelles

Multiple methods of micelle formation were investigated and compared using
dynamic light scattering (DLS). Syringe nanoprecipitation, solvent exchange, thin film
rehydration and chloroform emulsion evaporation were evaluated for their ability to
produce small micelles of low polydispersity. It was found that syringe nanoprecipitation
best met these criteria and was chosen as the standard procedure. In short, a dilute
solution of copolymer in tetrahydrofuran (THF) was stirred rapidly. To this solution,
distilled water was added dropwise and the THF was removed by dialysis against water.
Once prepared, micelles were characterized by DLS and transmission electron
microscopy (TEM). The results are summarized in Table 2.
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Table 3.2: Effect of PEO loading on micelles
Micelle Diameter a
Polymer

Micelle PDI
(nm)
Bimodal:
0.30

8
)

37.2, 172.3

9

64.7

0.40

10

123.8

0.15

Bimodal:
.0.44

11
38.1,184.0
aZ-average diameter determined by DLS

3.2.3

Effect o f PEO Loading on Micelle Formation

As shown in Figure 3.4, DLS analysis of micelles formed from polymer

8

exhibited a bimodal size distribution. It is likely that this results from aggregation of
individual micelles due to insufficient PEO. This hypothesis is supported by TEM
imaging (Figure 3.5) where it appears there are multiple particles adhered to one other.
Overall, this ratio of PEO does not produce particles of narrow enough polydispersity to
be useful clinically.

V olum e
Fraction

Volum e
Fraction

Vo lu m e
Fraction

V olum e
Fraction
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Figure 3.4: DLS traces for self assemblies formed from copolymers

\

8

to 11.
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Copolyrfier 8

**

♦Cop^ym^; 9

Figure 3.5: TEM images for self assemblies formed from copolymer 8 to 11.

In contrast, when micelles were prepared from polymer 9, a monomodal size
distribution was observed in the DLS analysis as shown in Figure 3.4. These micelles
have a diameter of approximately 65 nm, and this result was supported by TEM analysis
as shown in Figure 3.5.
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When micelle formation with polymer 10 was investigated, DLS analysis /
indicated that micelles increased in diameter to approximately 130 nm as shown in Figure
3.4. TEM imaging corroborates the size increase as shown in Figure 3.5.
DLS analysis of the micelles formed from polymer 11 revealed aggregation of the
micelles as shown in Figure 3.4. A TEM image of these micelles is shown in Figure 3.5.
These results show that the content of PEO obtained from conjugating PEO 2K is
insufficient to prevent the aggregation of the micelles.
Based on conjugation ratios, as well as, the ability to produce small, narrowly
dispersed micelles, 1.2 equivalents of PEO 5K was the ideal ratio. The small gain in
i

conjugation yield obtained from using 3 equivalents of PEO 5K does not compensate for
the increased difficulty of purification by preparative GPC. In addition, the sizes of the
micelles formed from polymer 9 are ideal for circulation in vivo . 1 1 ' 1 3 Since 50% of the
pendant amines are uncoupled, there is the possibility of conjugation of imaging agents or
for the covalent immobilization of drug molecules. Thus, further studies were carried out
using polymer 9.

3.2.4
3.2.4.1

Further Characterization and Release
Critical Aggregation Concentration

The critical aggregation concentration (CAC) is the concentration at which an
amphiphilic polymer forms aggregates in solution . 1 1 Nile Red, a hydrophobic dye shown
in Figure 3.6, was equilibrated with varying concentrations of micelles and the
fluorescence was measured. Nile Red is not soluble in water; therefore, it will not
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. fluoresce in aqueous media. It will, however, exhibit fluorescence upon encapsulation
within the hydrophobic core of a micelle . 1 2 By investigasting a series of increasingly
dilute samples, the CAC can be determined as the point where the concentration is too
low to form micelles and therefore Nile Red will not fluoresce. The range of polymer
concentrations under study was chosen by looking at previously published work of
similar systems . 2 , 1 1 ,1 2 According to Figure 3.7, all concentrations produced fluorescence,
which implies that at low concentrations, the micelles are likely unimolecular. 2

'I

Figure 3.6: Structure of the chosen model drug, Nile Red.
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Figure 3.7: Graph displaying results of CAC experiment. Florescence was observed at all
concentrations.

3.2.4.2

MTT Assay

In order to assess the toxicity of the micelles formed from copolymer 9, an MTT
Assay was run. In an MTT Assay, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) is reduced to purple formazan by living cells. Purple formazan is
insoluble, so a solubilizing solution is used to create a solution that can be measured
using UV-Vis spectroscopy. Since the reduction is done by living cells, the absorbance of
formazan will be proportional to the cell viability.

It was found that at concentrations up

to 2 mg/mL, the highest concentration investigated, the micelles produced no toxicity
(Figure 3.8).
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Figure 3.8: MTT cell viability study showing no cell toxicity.

3.2.4.3

Nile Red Release

In order to test the release kinetics of the micelles, a model drug, Nile Red, was
loaded and released. In order to load the micelles, Nile Red was dissolved in the initial
THF solution. Water was added dropwise with stirring and the THF was removed by
dialysis against water. Once all of the THF was removed, centrifugation was used to
remove any precipitated Nile Red. The micelle suspension was placed in a Slide-A-Lyzer
dialysis cassette and kept at 37 °C in pH 7.4 or 6.0 phosphate buffer or pH 5.0 citric
acid/phosphate buffer. The internal solution was measured in a fluorometer every hour
and was compared to a standard of Nile Red in THF that was kept in the fridge. The
results are summarized in Figure 3.9. The release in pH 5.0 and 6.0 are very similar,
achieving almost total release in 13 hours while the release took approximately

2 0

hours

in pH 7.4. It is hypothesized that the difference in release rates is due to the protonation
of the aniline nitrogens in Nile Red, which would facilitate its migration into the external
aqueous environment by increasing the polarity of Nile Red. It is predicted that the pKa
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- of the aniline nitrogens is between 5 and 6 . Methyl Red, a dye with aniline nitrogens in
a similar environment, has a pKa of 5.3 1 4 and Advanced Chemistry Development
(ACD/Labs) Software V11.02 (© 1994-2011 ACD/Labs) predicts the pKa as 5.4. Overall,
the results of this study show that this release rate would be suitable for in vivo drug
delivery applications . 1 8 ,1 9

Tim e (h)

Figure 3.9: Comparing Nile Red release from micelles at varying pHs.

3.2.4.4

Hydrolytic Degradation

As described above, as the PEA backbone contains hydrolysable linkages, the
polymer can be cleaved under physiological conditions to release smaller polymers. The
advantage of the degradation is that the higher MW polymer can be broken down into
smaller components that may eventually be excreted, rather than remain circulating in the
body. To examine the kinetics of this degradation, a study was performed. The micelles
were incubated in pH 7.4 phosphate buffer at 37 °C. At various time points, aliquots of
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the solution were removed, dried, and analyzed by GPC. As shown in Figure 3.10, a
side peak gradually appeared in the chromatogram suggesting the breakdown of the
polymer backbone which releases lower MW polymers over the time period of this study.
This study suggests that over time the micelles will break down in vivo, thus providing an
efficient means of leaving the body. ;

- - - Day 0
------- Day 16
..........Day 29

Figure 3.10: GPC micelle degradation study indicating that the copolymer breaks down
under physiological conditions.

3.3

v

Conclusions

A PEA containing pendant amine groups was synthesized as previously reported
and was reacted with activated PEO to produce novel PEO-PEA copolymers. Various
equivalents of PEO were investigated in this coupling and the micelles formed from the
resulting polymers were studied by DLS and TEM. The copolymer synthesis was
optimized to produce the smallest micelles with lowest polydispersities. It was found that
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. using 1.2 equivalents of PEO 5K relative to the pendant amines provided unimolecular
micelles of mean diameter 62 nm could be produced. The micelles were capable of
encapsulating and releasing hydrophobic compounds as exemplified by the model drug
Nile Red. The release occurs on a pharmacologically relevant time scale, with full release
occurring after approximately 20 hours in physiological conditions (pH 7.4 and 37 °C). A
degradation studied revealed that the polymer degraded gradually under physiological
conditions, providing a potential avenue for the eventual release of the materials from the
body." ■

3.4

Experimental

3.4.0

General Procedure and Methods

\ \

Solvents were purchased from Caledon Labs (Georgetown, ON). All other
chemicals were purchased from Sigma Aldrich (Milwaukee, WI) or Alfa Aesar (Ward
Hill, MA). Unless noted otherwise, all chemicals were used as received. Anhydrous
dichloromethane was distilled over CaH 2 . Infrared (IR) spectra were obtained using a
Bruker Tensor 27 instrument as films from dichloromethane on NaCl plates. !H NMR
spectra were obtained at 400 MHz on a Varian Mercury 400 Spectrometer. Chemical
shifts are" reported in ppm and are calibrated against residual solvent signals of CDCI3
(87.27). All coupling constants (J) are reported in Hz. Gel permeation chromatography
data were obtained using a Waters 2695 separations module equipped with a Waters 2414
refractive index detector (Waters Limited, Mississauga, ON) and two PLgel 5 pm mixedD (300 mm x 7.5 mm) columns connected in series (Varian Canada). Samples (5 mg/mL)
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- dissolved in the eluent, which comprised 10 mM LiBr and 1% (v/v) NEt3 in DMF at 85
°C were injected (100 pL) at a flow rate of 1 mL/min and calibrated against either
poly(styrene) or poly(ethylene glycol) standards.. Molecular weights are reported in
grams/mol (g/mol). Preparative GPC was equipped with a Waters 515 High performance
liquid chromatography (HPLC) pump set at a flow rate of 3mL/min. Separation was
achieved with two consecutively connected columns, a PLgel 10 pm 100 A (600x25 mm)
followed by a PLgel 10 pm 500 A (600x25 mm) and a preceding PLgel Prep Guard
column (25x25mm). Detection was obtained with a Wyatt Optilab Rex Refractive Index
detector. HPLC grade dimethylformamide with 1% triethylamine solvent was prepared
and filtered before eluting through columns. Dialysis was performed with Spectra/Por

6

dialysis tubing (Spectrum Laboratories, Rancho Dominguez, C A ).:

3.4.1

Synthesis o f Polymer 4

The di-p-toluenesulfonic acid salt monomer 1 (1.7 g, 2.3 mmol, 0.9 equiv.) and
sodium carbonate (0.54 g, 5.1 mmol, 2.0 equiv.) were dissolved in distilled water (30
mL). Diester 3 (0.14 g, 0.25 mmol, 0.1 equiv.) was dissolved in dichloromethane (15
mL) and added to the aqueous phase and allowed to mix for 30 min. Sebacoyl chloride
(0.55 mL, 2.6 mmol, 1.0 equiv.) diluted in anhydrous dichloromethane (15 mL), was
added dropwise over 30 min to the biphasic solution and was allowed to react for 24 h.
Upon completion of the reaction, solvent was removed in vacuo.

The functional

poly(ester amide) was redissolved in DMF permitting filtration of the insoluble salts.
The filtrate was then dialyzed against DMF for at least

8

h twice and then dried in vacuo
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providing polymer 4 as a sticky solid. Yield: 60%. Spectral data agreed with those
previously reported . 7 , 8 GPC (relative to PS standards): Mn = 48000, Mw = 73900, PDI =
1.5.

3.4.2

■.

.

'■ ' '

Synthesis o f Polymer 5

Polymer 4 (0.1 g, 0.18 mmol, 1.0 equiv.) was dissolved in 4 mL of 1:1
trifluoroacetic acid:dichloromethane in a flame dried flask and the reaction mixture was
/

stirred for 2 h under an argon atmosphere. The solvent was removed under a stream of
air with 3 washes of 15 mL of toluene to introduce an azeotrope. Residual solvent was
removed in vacuo resulting in a brown solid, polymer 5.

Yield: 99%. Spectral data

agreed with those previously reported . 8 , 9 GPC (relative to PS standards): Mn = 30400, Mw
= 40600, PDI =1.3.

3.4.3

Synthesis o f Activated Polyethylene oxide) (MW=5,000 g/mol) 6

v

5,000 g/mol polyethylene oxide) (10 g, 2.0 mmol, 1 eq) and 4-nitrophenyl
chloroformate (0.81 g, 4.0 mmol, 2.0 eq) were dissolved in dichloromethane (5 mL). To
this solution, pyridine (0.9mL, 8.0 mmol, 4.0 eq) was added dropwise and the reaction
was stirred overnight. The reaction was precipitated in cold ethyl ether (250 mL). The
precipitate was recovered, dried in vacuo, dissolved in dichloromethane and washed
twice in 1 M HC1. Yield: 92%. !H NMR (400 MHz, CDC13): 58.30-8.28 (d, 2H, Ar-H
ortho to N 0 2), 57.40-7.39 (d, 2H, A i-H meta to N 0 2), 4.46-4.44 (-CH2 -0-C (0)-0-), 3.65
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- (br s, 449H, -0-C H 2-CH2-0-), 3.39 (s, 3H ,-0-C //i). FTIR (cm'1): 2880 (sp3 C-H
stretch), 1765 (C =0 stretch), 1526 (CH 2 bend, C=C ring stretch), 1462 (CH 3 bend, C=G
ring stetch), 1380 (symetic Ar-N 0

2

stretch), 1259 (A r-0 stretch), 1111 (assymetric C-O-

C stretch), 847 (out of plane C-H on Ar bending). GPC (relative to PEO standards): Mn =
4500, Mw = 4600, PDI = 1.08.

3.4.4

Synthesis o f Activated Poly(ethylene oxide) (MW-2 000 g/mol) 7

The same procedure for the synthesis of polymer

6

was used except that 2000

g/mol poly(ethylene glycol) (4 g, 2.0 mmol, 1.0 eq) was used instead. Yield: 75%. !H
NMR (400 MHz, CDC13): 58.28-8.25 (d, 2H, Ar-H ortho to N 0 2), 57.39-7.37 (d, 2H, Ar
i f meta to N 0 2), 4.45-4.43 (-CH2-O-C(O)-O-), 3.62 (br s, 449H, -0-CH 2-CH2-0-), 3.36
(s, 3H,-0-CH5). FTIR (cm'1): 2883 (sp 3 C-H stretch), 1769 (C =0 stretch), 1526 (CH 2
bend, C=C ring stretch), 1468 (CH 3 bend, C=C ring stetch), 1360 (symetic Ar-N 0 2
stretch), 1280 (A r-0 stretch), 1115 (assymetric C-O-C stretch), 843 (out of plane C-H on
Ar bending). GPC (relative to PEG standards): Mn= 1700, Mw= 1800, PDI =1.1.

3.4.5

Synthesis o f PEO-PEA Copolymer 8
)
The p-nitrophenyl functionalized 5000 g/mol poly(ethylene glycol), 6 , (0.0653 g,

0.01 mmol, 0.85 eq relative to the number of lysine residues), deprotected lysine PEA, 5,
(0.0526 g, 0.01 mmol), and 4-(dimethylamino)pyridine (DMAP) (0.4 mg, 2.98 pmol, 0.2
eq relative to the number of lysine residues) were added to a flame dried flask in an argon
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- atmosphere. Dichloromethane (4 mL) was added to dissolve the solids. Upon
dissolution, diisopropylethylamine (DIPEA) (0.004 g, 0.03 mmol, 2 eq relative to the
number of lysine residues) was added dropwise. The reaction mixture was allowed to stir
overnight. The solvent was removed in vacuo and the product was dialyzed against DMF
using a membrane with a with MWCO 25,000 g/mol. The solvent was removed in vacuo
and the off-white solid was separated from any uncoupled PEG through preparative GPC.
The solvent was removed in vacuo yielding polymer 8 . Yield: 25%.

NMR (400 MHz,

CDC13): 57.26-7.05 (m, 9H, Ph), 6.00-5.94 (br m, 1.8H, -C(0)-NH-CaH-CH 2 -Ph), 4.864.79 (m, 1.8, -C„H-CH 2 -Ph), 4.50 (br m, 0.2H, -NH-C(O)-O-), 4.12-3.97 (m, 4H, C (0)0-C H 2-), 3.65 (br m, 24H,-0-C/72-CH2-0-), 3.37 (s, 0.2H, -O-CH 3 ), 3.09-3.00 (m,
3.8H, -CaH-CH 2 -Ph), 2.13-2.09 (m, 4H, -NH-C(0)-Ctf2-), 1.55-1.50 (m, 8 H, -C (0 )0 CU 2-CH 2-, -NH-C(0)-CH 2 -Ctf2-), 1.23-1.19 (m, 8 H, -NH-C(0)-CH 2 -CH 2 -(CH2)4). FTIR
(cm '1): 3100 (N-H stretch), 3030 (sp 2 C-H stretch), 2883 (sp3 C-H stretch), 1745 (C =0
etser stretch), 1690 (C =0 amide stretch), 1550 (N-H bending), 1526 (CH 2 bend, C=C
ring stretch), 1468 (CH 3 bend, C=C ring stetch), 1400 (C-N stretch), 1115 (assymetric CO-C stretch), 999 (C-O stretch), 850 (symmetric C-O-C stretching), 843 (out of plane CH on Ar bending), 750 (monosubstituted Ar C-H bending) 690 (monosubstituted Ar C-H
bending). GPC (relative to PEO Standards): Mn = 30000, Mw= 45700, PDI = 1.5.

3.4.6

Synthesis o f PEO-PEA Copolymer 9

The same procedure described above for polymer

8

was used except that 1.2

equivalents of p-nitrophenyl carbonate activated PEO 5K relative to the number of lysine
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. residues was used. Yield: 27%. !H NMR (400 MHz, CDC13): 57.28-7.09 (m, 9H, Ph),
6.28 (br m, 0.2H, -C(0)-N tf-CaH-(CH 2 )4 -NH -C (0)-0-) 6.01-6.00 (br m, 1.8H, -C(O)NH-CaH-CH 2 -Ph), 4.88-4.84 (m, 1.8, -C„tf-CH 2 -Ph), 4.54 (br m, 0.2H, -Ntf-C(O)-O-),
4.12-4.01 (m, 4H, -C (0 )0 -C /i2-), 3.65 (br m, 45H,-0-C/7 2 -C772 -0-), 3.37 (s, 0.3H, -OCH3), 3.12-3.03 (m, 3.8H, -C«H-Ctf2 -Ph), 2.18-2.12 (m, 4H ,-N H -C (0)-C //2-), 1.57-1.52
(m,

8

H, -C (0)0-C H 2 -Ctf 2 -,-N H -C (0)-C H 2 -Ctf2-), 1.28-1.22 (m,

8

H, -NH-C(0)-CH2-

CH 2 -(CH2)4). FTIR (cm'1): 3110 (N-H stretch), 3032 (sp2 C-H stretch), 2886 (sp3 C-H
stretch), 1755 (C =0 etser stretch), 1696 (C =0 amide stretch), 1551 (N-H bending), 1528
(CH 2 bend, C=C ring stretch), 1468 (CH 3 bend, C=C ring stetch), 1405 (C-N stretch),
1114 (assymetric C-O-C stretch), 979 (C -0 stretch), 853 (symmetric C-O-C stretching),
843 (out of plane C-H on Ar bending), 737 (monosubstituted Ar C-H bending) 692
(monosubstituted Ar C-H bending). GPC (relative to PEO standards): Mn= 31000, Mw=
48600, PDI =1.6.

3.4.7

Poly (ester amide )-co-poly(ethylene glycol) using 3.0 eq o f 5000 g/mol PEG, 10

The same procedure described above for polymer

8

was used except that 3.0

equivalents of p-nitrophenyl carbonate activated PEO 5K relative to the number of lysine
residues was used. Yield: 30%. lH NMR (400 MHz, CDC13): 57.30-7.10 (m, 9H, Ph),
6.06-6.04 (br m, 1.8H, -C (0)-N tf-CaH-CH 2 -Ph), 4.88-4.86 (m, 1.8, -Catf-CH 2 -Ph), 4.134.02 (m, 4H, -C (0 )0 -C tf2-), 3.65 (br m, 56H,-0-CH2-Ci72-0-), 3.39 (s, 0.4H, -O-CH3),
3.11-3.08 (m, 3.8H, -CaH-C/72 -Ph), 2.22-2.14 (m, 4H, -NH-C(0)-C/72-), 1.89-1.69 (m,
8

H, -C (0)0-C H 2 -CH2-, -NH-C(0)-CH 2 -C/f2-), 1.28-1.26 (m, 8.4H, -NH-C(0)-CH 2 -CH2-
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- (Ctf2)4). FTIR (cm'1): 3110 (N-H stretch), 3061 (sp2 C-H stretch), 2881 (sp 3 C-H
stretch), 1746 (C =0 etser stretch), 1678 (C =0 amide stretch), 1523 (N-H bending), 1523
(CH 2 bend, C=C ring stretch), 1476 (CH 3 bend, C=C ring stetch), 1369 (C-N stretch),
1119 (assymetric C-O-C stretch), 1001 (C -0 stretch), 851 (symmetric C-O-C stretching),
853 (out of plane C-H on Ar bending), 751 (monosubstituted Ar C-H bending) 694
(monosubstituted Ar C-H bending). GPC (relative to PEO standards): Mn= 34000, Mw=
42000, P D I= 1.2.

3.4.8

;

Poly(esteramide)-co-poly(ethylene glycol) using 1.2 eq of2000g/mol PEG, 11

The same procedure described above for polymer

8

was used except that 1.2

equivalents of p-nitrophenyl carbonate activated PEO 2K relative to the number of lysine
residues was used. Yield: 28%. !H NMR (400 MHz, CDC13): 57.28-7.10 (m, 9H, Ph),
6.29 (br m, 0.2H, -C(0)-N //-C aH-(CH 2 )4 -NH -C (0)-0-) 6.01-6.00 (br m, 1.8H, -C(O)N //-C aH-CH 2 -Ph), 4.88-4.85 (m, 1.8, -Catf-CH 2 -Ph), 4.54 (br m, 0.2H, -Ntf-C(O)-O-),
4.12-4.01 (m, 4H, -C (0 )0 -C tf2-), 3.65 (br m, 19H,-0-Ctf2-Ctf2-0-), 3.38 (s, 0.3H, -O}
CHs), 3.15-3.05 (m, 3.8H, -CaH-Ctf 2 -Ph), 2.21-2.12 (m, 4H, -NH-C(0)-Ctf2-), 1.57-1.55
(m, 8 H, -C (0)0-C H 2 -Ctf2-, -NH-C(0)-CH 2 -C/72-), 1.26-1.22 (m, 8.4H, -NH-C(0)-CH2CH 2 -(CH 2)a). FTIR (cm'1): 3099 (N-H stretch), 3022 (sp2 C-H stretch), 2880 (sp3 C-H
stretch), 1749 (C =0 etser stretch), 1693 (C =0 amide stretch), 1556 (N-H bending), 1527
(CH 2 bend, C=C ring stretch), 1468 (CH 3 bend, C=C ring stetch), 1429 (C-N stretch),
1107 (assymetric C-O-C stretch), 992 (C -0 stretch), 851 (symmetric C-O-C stretching),
832 (out of plane C-H on Ar bending), 758 (monosubstituted Ar C-H bending) 687
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- (monosubstituted Ar C-H bending). GPC (relative to PEO standards): Mn= 24000, Mw
= 34000, PDI = 1.4.

3.4.9

Micelle Formation

The PEA-PEG copolymer, one of 8-11 (2.5 mg), was dissolved in 0.5 mL of THF
and was stirred rapidly. To this solution, 2 mL of distilled water was added dropwise. The
THF was removed by dialysis against water with a regenerated cellulose membrane of
MWCO 12-14 kg/mol for 24 hours with the dialysate being replaced every

8

hours.

3.4.10 Determination o f CAC

The PEA-PEG copolymer, 9 (2.5 mg), was dissolved in 0.5 mL of THF and
stirred rapidly. To this solution, 2 mL of distilled water was added dropwise. The THF
was removed by dialysis against water with a regenerated cellulose membrane of MWCO
12-14 kg/mol for 24 hours with the dialysate being replaced every

8

hours. Nile Red

i

(0.94 mg, 3.0 pmol) was dissolved in 9 mL of CH 2 CI2 and 0.1 mL of this solution was
added to a series of 12 vials. The CH 2 CI2 was removed under a stream of air. A series of
concentrations of the micelle dispersion ranging from to 0.0005 mg/mL to 1 mg/mL was
made by dilution with pH 7.4, 100 mM phosphate buffer. The dilute dispersions were
added to the vials containing Nile Red and were allowed to equilibrate with stirring for
40 hours. The fluorescence spectra were obtained on a QM-4 SE spectrometer from
Photon Technology International (PTI), equipped with double excitation and emission
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. monochromators. An excitation wavelength of 550 nm was used for Nile Red and the
emission spectra were recorded from 565 and 700 nm. The maximum emission intensity
was obtained for each micelle concentration.

:

3.4.11 M TT Procedure

Proliferation of HeLa cells were measured by an MTT assay. [19] Cells were
seeded into

8 8

wells of a 96-well plate (Nunclon TC treated) at a density of 2x10 cells

per well in a final volume of 100 pL of Dulbecco’s Modified Eagle Medium (DMEM)
containing 10% serum and 1% antibiotics. Cells were allowed to adhere for 24 hours at
37 °C in a humidified incubator with 5% CO 2 . After 24 hours the growth media was
aspirated. Control cells were grown in growth media alone while nanoparticle samples
were incubated in two-fold decreasing concentrations from 2 mg/ml to 0.0039 mg/mL in
growth media with

8

replicates at each concentration for 48 hours.

All media was

aspirated then 100 pL of fresh media and 10 pL of MTT solution (5 mg/mL) was added
to each well and incubated for another 4 hours.

The media was aspirated and the

formazan product was solubilized by addition of 50 pL DMSO to each well. Absorbance
of each well was measured at 540 nm using a plate reader (Tecan Safire).

3.4.12 Encapsulation and Release o f Nile Red

The PEA-PEG copolymer, 10 (2.5 mg), and Nile Red (0.5 mg, 1.6 pmol) were
dissolved in 0.5 mL of THF and stirred rapidly. To this solution, 2 mL of distilled water
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. was added dropwise. The THF was removed by dialysis against water with a
regenerated cellulose membrane of MWCO 12-14 kg/mol for 24 hours with the dialysate
being replaced every

8

hours. Once all of the THF was removed, centrifugation (6000

rpm for 30 min) was used to remove any precipitated Nile Red. The micelle suspension
was placed in a Slide-A-Lyzer dialysis cassette and kept at 37°C in either pH 7.4 or 6.0,
100 mM phosphate buffer or pH 5.0, 100 mM citric acid/phosphate buffer. The
fluorescence spectra were obtained on a QM-4 SE spectrometer from Photon Technology
International (PTI), equipped with double excitation and emission monochromators. An
excitation wavelength of 550 nm was used for Nile Red and the emission spectra were
recorded from 565 and 700 nm. A measurement was obtained every hour and was
compared to a standard of Nile Red in THF which was covered in aluminum foil and kept
j

,

in fridge.

3.4.13 Hydrolytic Degradation o f Micelles

The PEA-PEG copolymer 10 (39 mg) was dissolved in 4 mL of THF and stirred
rapidly. To this solution, 16 mL of distilled water was added dropwise. The THF was
removed by dialysis against water with a regenerated cellulose membrane of MWCO 1214 kg/mol for 24 hours with the dialysate being replaced every

8

hours. The dispersion

was concentrated to 3 mL using a stream of air and was then placed in a Slide-A-Lyzer
dialysis cassette with a MWCO of 3,500 g/mol. The cassette was kept in pH 7.4 100 mM
phosphate buffer at 37 °C with stirring. Samples were removed periodically from the
internal solution and lyophilized before analysis by GPC.
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3.4.14 TEM Sample Preparation

A micelle solution of 0.2 mg/mL was prepared and 20 pL of this was placed on a
copper TEM grid and allowed to dry overnight. Transmission electron microscopy
(TEM) was carried out using a carbon Formvar grid and a Phillips CM 10 microscope
operating at 80 kV with a 40 pm aperture.

I
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Chapter Four:
Conclusion
4.1

Thesis Summary
In the first part of this thesis, the use of poly(ester amide)s (PEA)s containing

pendant functional groups for the preparation of drug delivery nanoparticles (NP)s was
explored. By employing a more powerful emulsifying method and running a series of
optimization experiments, the procedure for preparing nanoparticles based on PEAs was
significantly improved relative to previously reported routes ’ by providing nanosized
particles with low polydispersity indices. In addition, it was possible for the first time, to
prepare these particles from PEAs with carboxylic acid functional handles. To investigate
the potential use of these functional handles for the covalent immobilization of drug
molecules, an alcohol functionalized Rhodamine B derivative was chosen as a model
drug and was coupled to the PEA via an ester linkage prior to nanoparticle preparation. It
was found that the covalently immobilized model drug was released much more slowly
than a physically encapsulated control. While the physically encapsulated Rhodamine
was completely released in 9 hours, only approximately 10% of the covalently bound
drug was released in the same time frame. This result suggests that the covalently bound
system would be effective as a sustained delivery vehicle, avoiding the undesirable burst
release seen in currently used chemotherapy systems. ’ In addition, this system can be
dried and reconstituted for convenient storage and transport. Overall, this nanocarrier
displays great promise for applications in sustained release drug delivery.
The covalently immobilized system did have a drawback in that relatively large
amounts of poly(vinyl alcohol) (PVA) were required in order to obtain NPs small enough
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. to remain circulating for extended periods as well as extravasate into cancerous tissue.
Problems may arise as PVA may mask the desirable properties of the PEA such as
slowing its biodegradation, and preventing the conjugation of targeting molecules to the
PEA’s pendant functional groups. The PVA layer may also impede diffusion from the
nanoparticle and may increase the minimum particle diameter by increasing external
phase viscosity at higher concentrations . 6
In order to overcome these issues, novel poly(ethylene oxide)-poly(ester amide)
(PEO-PEA) copolymers were synthesized. By imparting amphiphilic properties to the
PEA, the need for surfactant was eliminated and the resulting copolymer self-assembled
into micelles in aqueous media. The micelle formation procedure was optimized to
produce micelles less than 100 nm in diameter with low polydispersities. By
characterization with dynamic light scattering and transmission electron microscopy it
was found that micelles of mean diameter 62 nm could be produced with a PDI of 0.4.
The micelles were capable of encapsulating and releasing hydrophobic compounds as
exemplified by the encapsulation and release of Nile Red. The release occurs on a
\
pharmacologically relevant time scale, with full release occurring after approximately

2 0

hours under physiological conditions. The release rate increased at lower pH, such as
would be found in the acidic environment of a tumour cell; however, it was hypothesized
that the change in release was due to protonation of the Nile Red and not due to pH
sensitivity of the copolymer. The degradation of the micelles in phosphate buffer was
studied by gel permeation chromatography and it was found that the polymer degraded
gradually, suggesting that the copolymers would be hydrolyzed in vivo, providing a route
for the eventual excretion of the polymers from the body. Overall, these results suggest
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- that micelles derived from PEO-PEA copolymers are promising materials for drug
delivery applications.
PEAs offer several properties superior to currently used systems such as fewer
acidic degradation products and functional handles for the conjugation of bioactive
molecules. Though still in the early phase of evaluation, through characterization and
release studies, PEAs are being revealed as promising drug delivery vehicles. Overall, the
results obtained in this thesis suggest that PEAs are excellent biomaterials, capable of
delivering therapeutics and potentially overcoming many of the deficiencies found in
current delivery systems.

, ■

4.2

Future Work

4.2.1

Covalent Immobilization o f Drug Molecules in Poly(ester amide) Nanoparticles

A variety of drugs should be coupled to the PEA to establish the versatility of this
drug delivery system. Biological assays should be performed to determine cell uptake and
in vitro toxicity of both the empty and drug loaded NP. If these results are promising, the
carriers should then be evaluated in vivo to determine their biocompatibility,
biodistribution behavior and therapeutic efficacy. Eventually, targeting ligands could be
incorporated in order to increase the specificity of the system for disease targets such as
cancerous tumours.

98
. 4.2.2

Development o f Poly(ethylene oxide)-Poly(ester amide) Graft Copolymers fo r

Micellar Drug Delivery Vehicles
\

Clinically used drugs should be encapsulated within micelles and their release
properties investigated in order to determine behavior and the versatility of the
nanocarrier system. Biological assays should be performed to determine the cell uptake,
intracellular localization, and toxicities of these systems, while in vivo studies will reveal
their therapeutic potential. In the longer term, the addition of targeting groups to the
terminus of the PEO chain may lead to improvements in the system’s efficacy.

4.2.3

Combination o f Projects

It is intended that aspects of the two delivery systems be combined. For example,
drugs can be covalently bound to the interior of a micelle, where they will be well
protected from the'in vivo environment but will still degrade in a sustained release
fashion. The projects were kept separate in this thesis in order to develop the methods and
to elucidate the properties of each system, but in the future it should be possible to
combine the developed methods to attain the best properties of each system.

J
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